研究者詳細 - 本多　隆

論文 - 本多　隆

分割表示 >> ／全件表示 256 件中 1 - 256 件目

*Gut Microbes Associated with Functional Cure of Chronic Hepatitis B 査読有り国際誌

Honda T*, Ishigami M, Ishizu Y, Imai N, Ito T, Yamamoto K, Yokoyama S, Muto H, Inukai Y, Kato A, Murayama A, Yoshio S, Ishikawa T, Fujishiro M, Kawashima H, Kato T.

Hepatology International 2025年1月

Differential HCC risk among HBV indeterminate types at baseline and by phase transition 査読有り国際共著

Huang R, Trinh HN, Yasuda S, Chau A, Maeda M, Do AT, Huang DQ, Ito T, Honda T, Ishigami M, Kozuka R, Preda CM, Tseng CH, Marciano S, Tsai PC, Lee DH, Wong CC, Do S, Kawashima K, Zhang J, Marin RI, Sandra I, Li J, Ogawa E, Cheung R, Li J, Yu ML, Gadano A, Hsu YC, Buti M, Enomoto M, Lim SG, Wu C, Toyoda H, Nguyen MH.

Gut. 2025年6月

Clinical Characteristics of Immune Checkpoint Inhibitor-Related Pancreatic Injury with Pancreatitis in Patients with Advanced Malignancies 査読有り Open Access

Suzuki T, Mizuno K, Yamamoto T, Ito T, Ishikawa T, Honda T, Akamatsu S, Ishii M, Ando Y, Kawashima H.

Dig Liver Dis. 57 巻頁： 1230 - 1237 2025年6月

Distribution, characteristics, and natural history of diverse types of indeterminate chronic hepatitis B: a REAL-B study 査読有り国際共著

Huang R, Do AT, Toyoda H, Li J, Yasuda S, Tsai PC, Yeh ML, Trinh H, Chau A, Huang DQ, Ogawa E, Ito T, Kozuka R, Atsukawa M, Marciano S, Honda T, Watanabe T, Itokawa N, Preda CM, Tseng CH, Barreira A, Inoue K, Takahashi H, Uojima H, Kawashima K, Hsu YC, Marin RI, Sandra I, Ishigami M, Li J, Zhang J, Do S, Maeda M, Lee DH, Chuang WL, Dai CY, Huang JF, Huang CF, Cheung R, Buti M, Tanaka Y, Yuen MF, Enomoto M, Gadano A, Lim SG, Yu ML, Wu C, Nguyen MH.

Aliment Pharmacol Ther. 2025年5月

Steroid Initiation Dose and Duration of Steroid Reduction for Immune Checkpoint Inhibitor-Induced Liver Injury 査読有り

Yamamoto T, Ito T, Suzuki T, Mizuno K, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H.

Hepatol Res. 2025年5月

Pathological significance of intranuclear structures in liver biopsy samples 招待有り査読有り Open Access

Imai N, Ohsaki Y, Cheng J, Kawecka H, Zhang J, Mizuno F, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishikawa T, Woźniak M, Wake H, Kawashima H.

Hepatol Res. 2025年5月

A Novel Clip Device for Safer and Faster Suturing in Endoscopic Papillectomy: A Retrospective Study of 241 Procedures 査読有り

A Novel Clip Device for Safer and Faster Suturing in Endoscopic Papillectomy: A Retrospective Study of 241 Procedures

J Gastroenterol Hepatol. 40 巻 ( 5 ) 頁： 1238 - 1244 2025年5月

Ampullary tumors exhibit increased fusobacterium in both the tumor surface and surrounding duodenal mucosa during carcinoma progression 査読有り Open Access

Takada Y, Yamamoto K, Ishikawa T, Yamao K, Mizutani Y, Iida T, Uetsuki K, Hirose T, Maeda K, Yamamura T, Furukawa K, Ohno E, Nakamura M, Honda T, Kawashima H.

Sci Rep. 15 巻 ( 1 ) 頁： 14916 2025年4月

Decline of Persistent Jaundice in a Patient With Autoimmune Hepatitis and Vanishing Bile Duct Syndrome Treated With Elobixibat for Constipation 査読有り国際共著 Open Access

Trần Thị T, Imai N, Inukai Y, Honda T, Kawashima H.

Cureus. 17 巻 ( 3 ) 頁： e80021 2025年3月

Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment 査読有り国際共著国際誌

Huang R, Jun DW, Toyoda H, Hsu YC, Trinh H, Nozaki A, Ishikawa T, Watanabe T, Uojima H, Huang DQ, Honda T, Tanaka Y, Vutien P, Marciano S, Abe H, Enomoto M, Atsukawa M, Takahashi H, Tsuji K, Takaguchi K, Tsai PC, Dai CY, Huang JF, Huang CF, Yeh ML, Yoon E, Kim SE, Ahn SB, Kim GA, Jung JH, Jeong SW, Oh H, Tseng CH, Ishigami M, Chau A, Maeda M, Yasuda S, Chuma M, Ito T, Kawashima K, Liu JK, Gadano A, Kozuka R, Itokawa N, Inoue K, Senoh T, Li J, Chuang WL, Cheung R, Wu C, Yu ML, Nguyen MH.

Clin Mol Hepatol. 2025年3月

Current management and future perspectives of covert hepatic encephalopathy in Japan: A nationwide survey 査読有り国際誌

Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, Ohara M, Arai T, Tamai Y, Isoda H, Tadokoro T, Hanai T, Ito T, Tamaki N, Sakamaki A, Aoki Y, Tada F, Yoshio S, Takahashi H, Morishita A, Ishikawa T, Inoue J, Suda G, Ogawa C, Atsukawa M, Hiraoka A, Kuroda H, Namisaki T, Honda T, Kawaguchi T, Tanaka Y, Terai S, Ikegami T, Yoshiji H, Iwasa M, Shimizu M.

J Gastroenterol. 2025年3月

Prognostic Role of Enhancing Mural Nodules in Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata 査読有り国際誌

Kumano R, Ohno E, Ishikawa T, Yamao K, Mizutani Y, Iida T, Uetsuki K, Yamamura T, Furukawa K, Nakamura M, Honda T, Kawashima H.

Ann Surg 2025年2月

Type 2 diabetes and hypertension as risk factors for advanced fibrosis in biopsy proven metabolic dysfunction–associated steatotic liver disease" in its current form for publication in Journal of Digestive Diseases. 査読有り国際誌

Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Shimizu T, Hattori M, Takeyama T, Ando Y, Nishikawa T, Morita K, Toyoda H, Ishigami M, Kawashima H

J Dig Dis 2025年1月

A newly proposed endoscopic score system to evaluate the entire small bowel and predict the prognosis in Crohn's disease 査読有り国際誌

Tanaka H, Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishikawa T, Ishizu Y, Furukawa K, Honda T, Uchida G, Kawashima H

Nagoya J Med Sci. 2025年1月

Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors 査読有り国際誌

Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, Toyoda H, Ando Y, Shimoyama Y, Kawashima H

Dig Liver Dis. 2025年1月

A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment 査読有り国際誌

Imai N, Yamamoto T, Mizuno K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Kawashima H.

Cancers 16 巻 ( 22 ) 頁： 3797 2024年11月

Modified FIB-4 Index in Type 2 Diabetes Mellitus with steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis 査読有り国際共著国際誌

Kim J, Ito T, Arai T, Atsukawa M, Kawanaka M, Toyoda H, Honda T, Yu ML, Yoon EL, Jun DW, Cha K, Nguyen MH

Diagnostics 14 巻 ( 22 ) 頁： 2500 2024年11月

The distribution of FIB-4 and VCTE-derived LSM for patients with MASLD in health check-up 査読有り国際誌

Ogawa Y, Tomeno W, Imamura Y, Baba M, Ueno T, Kobayashi T, Iwaki M, Nogami A, Kessoku T, Honda Y, Notsumata K, Fujikawa H, Kaai M, Imajo K, Kawanaka M, Hyogo H, Hisatomi M, Takeuchi M, Hakamada T, Honda T, Tatsuta M, Morishita A, Mikami S, Furuya K, Manabe N, Kamada T, Kawaguchi T, Yoneda M, Saito S, Nakajima A

Hepatol Res. 2024年10月

Identification of Two Long Noncoding RNAs, Kcnq1ot1 and Rmst, as Biomarkers in Chronic Liver Diseases in Mice 査読有り国際誌

Yokoyama S, Muto H, Honda T, Kurokawa Y, Ogawa H, Nakajima R, Kawashima H, Tani H.

Int J Mol Sci 25 巻 ( 16 ) 頁： 8927 2024年10月

High-Fat Diet Modulates Bile Acid Composition and Gut Microbiota, Affecting Severe Cholangitis and Cirrhotic Change in Murine Primary Biliary Cholangitis 査読有り国際誌

Umemura M, Honda A, Yamashita M, Chida T, Noritake H, Yamamoto K, Honda T, Ichimura-Shimizu M, Tsuneyama K, Miyazaki T, Kurono N, Leung PSC, Gershwin ME, Suda T, Kawata K.

Journal of Autoimmunit 2024年9月

Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma 査読有り国際誌

Yamamoto T, Ito T, Mizuno K, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H.

Anticancer Res 44 巻 ( 9 ) 頁： 4101 - 4111 2024年7月

Clinical Outcomes of Use of the Porous Glass Membrane Pumping Emulsification Device During Transarterial Chemoembolization for Hepatocellular Carcinoma 査読有り国際誌

Mizuno F, Imai N, Mizuno K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kawashima H.

Anticancer Res. 44 巻 ( 7 ) 頁： 3185 - 3191 2024年7月

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study 査読有り国際共著国際誌

Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, Toyoda H, Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CP, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VW, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwara E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Xuan Tay W, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH.

J Clin Transl Hepatol 28 巻 ( 7 ) 頁： 646 - 658 2024年7月

Predicting Early Rebleeding and Mortality After Endoscopic Hemostasis of Esophagogastric Varices: Diagnostic Performance of Aspartate Aminotransferase-to-Platelet Ratio Index and Model for End-Stage Liver Disease-Na Score 査読有り国際誌

Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Mizuno K, Nakamura N, Kawashima H

J Hepatobiliary Pancreat Sci. 2024年7月

Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center 査読有り国際誌

Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Mizuno K, Kojima T, Kariya N, Nakamura N, Kawashima H

Clinical Nutrition 43 巻 ( 6 ) 頁： 1425 - 1432 2024年6月

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team 査読有り国際誌

Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Hama M, Kataoka T, Shimokata T, Ando Y, Kawashima H.

Hepatol Res. 2024年4月

Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma 査読有り国際誌

Inukai Y, Yamamoto K, Honda T*, Yokoyama S, Ito T, Ishigami M, Kawashima H

Cancers 26 巻 ( 16 ) 頁： 1675 2024年4月

Identification of the microbiome associated with prognosis in patients with chronic liver disease 査読有り国際誌

Yamamoto K, Honda T, Inukai Y, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Kawashima H

Microorganisms 12 巻 ( 3 ) 頁： 610 2024年3月

Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors 査読有り国際誌

Shibata H, Yamamoto K, Hirose T, Furune S, Kakushima N, Furukawa K, Nakamura M, Honda T*, Fujishiro M, Kawashima H.

Dig Liver Dis 2024年2月

Analysis of Neuropeptides in the Intestinal Mucus of Patients with Ulcerative Colitis Using RNA Sequencing 査読有り国際誌

Nakamura M, Murate K, Maeda K, Yamamura T, Sawada T, Ishikawa E, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion 105 巻 ( 5 ) 頁： 400 - 410 2024年

Long-term monitoring and clinical implications of small bowel capsule endoscopy in patients with Crohn's disease with small bowel lesions: A Retrospective Analysis 査読有り国際誌

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Murate K, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion 105 巻 ( 5 ) 頁： 380 - 388 2024年

*Effects of 1‐kestose on microbiome changes caused by vonoprazan: a randomized, double‐blind, placebo‐controlled pilot study 査読有り国際誌

Furune S, Suzuki T, Honda T*, Yamamoto K, Furukawa K, Nakamura M, Ishigami M, Kinoshita F, Kadota Y, Tochio T, Shimomura Y, Hirooka Y, Fujishiro M, Hirroka Y, Kawashima H

J Gastroenterol Hepatol. 2023年12月

Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function 査読有り国際誌

Ikegami S, Maeda K, Urano T, Mu J, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Yamamoto K, Muto H, Oishi A, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Ishigami M, Kawashima H.

Inflamm Bowel Dis 2023年12月

*Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. 査読有り国際誌

Sugiyama Y, Yamamoto K, Honda T*, Kato A, Muto H, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Asano T, Enomoto A, Zaitsu K, Ishigami M, Fujishiro M, Kawashima H

Hepatology international 17 巻 ( 6 ) 頁： 1378 - 1392 2023年12月

A new criterion including the aspartate aminotransferase-to-platelet ratio index and liver and spleen stiffness to rule out varices needing treatment in children with biliary atresia: Modification of the Baveno VII criteria. 査読有り国際誌

Hepatology research : the official journal of the Japan Society of Hepatology 2023年10月

Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia. 査読有り国際誌

European journal of gastroenterology & hepatology 35 巻 ( 10 ) 頁： 1211 - 1215 2023年10月

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis. 査読有り国際誌

Inflammatory intestinal diseases 8 巻 ( 2 ) 頁： 60 - 68 2023年10月

Clinical characteristics of Dieulafoy’s Lesion in the Small Bowel Diagnosed and Treated by Double-Balloon Endoscopy 査読有り国際誌

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Furukawa K, Iida T, Mizutani Y, Yamao K, Ishikawa T, Honda T, Ishigami M, Kawashima H.

BMC Gastroenterol. 23 巻 ( 1 ) 頁： 290 2023年8月

Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply. 査読有り国際誌

Alimentary pharmacology & therapeutics 57 巻 ( 11 ) 頁： 1351 - 1352 2023年6月

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis. 査読有り国際誌

Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima

Investigational new drugs 41 巻 ( 3 ) 頁： 512 - 521 2023年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In this study, we aimed to summarize the clinical features of irSC. Clinical data were collected retrospectively from 1,393 patients with advanced malignancy treated with immune-checkpoint inhibitors (ICIs) between August 2014 and October 2021. We analyzed patients with immune-related adverse events of liver injury (liver-irAEs) and compared irSC and non-irSC groups. Sixty-seven patients (4.8%) had a liver-irAE (≥ grade 3) during the follow-up period (median, 262 days). Among these, irSC was observed in eight patients (11.9%). All patients in the irSC group were treated with anti-PD-1/PD-L1 antibodies. Compared with the non-irSC group, the irSC group showed mainly non-hepatocellular liver injury (87.5 % vs 50.8 %, P = 0.065), and had elevated serum inflammatory markers (e.g., CRP and NLR) and biliary enzymes (e.g., GGTP and ALP) at the onset of liver-irAEs. Furthermore, most patients with irSC had abdominal pain. In the non-irSC group, the liver injury of 23 patients improved only with the discontinuation of ICIs, and 22 patients improved with medication including prednisolone (PSL). Conversely, almost all patients (n=7) in the irSC group were treated with PSL, but only two patients experienced an improvement in liver injury. We found that irSC is characterized by a non-hepatocellular type of liver injury with abdominal pain and a high inflammatory response and is refractory to treatment. Further examination by imaging is recommended to detect intractable irSC in cases with these characteristics.

DOI： 10.1007/s10637-023-01366-3

Scopus

PubMed

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma. 査読有り国際誌

Mizuno K, Imai N, Yamamoto T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kuzuya T, Ishigami M, Kawashima H

Cancers 15 巻 ( 10 ) 2023年5月

Successful Treatment with Steroids in a Patient with Vanishing Bile Duct Syndrome and Acute Tubular Necrosis. 査読有り国際誌

Mizuno F, Imai N, Yasuda K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Kawashima H

Internal medicine (Tokyo, Japan) advpub 巻 ( 0 ) 2023年5月

Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases. 査読有り国際誌

Imai N, Ohsaki Y, Cheng J, Zhang J, Mizuno F, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Wake H, Kawashima H

Scientific reports 13 巻 ( 1 ) 頁： 6851 2023年4月

*Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet 招待有り査読有り国際誌

Muto H, Honda T, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Imai N, Ishizu Y, Maeda K, Ishikawa T, Adachi S, Chikara Sato C, Tsuji M N, Fujishiro M, Kawashima H

Nutrients 15 巻 ( 1473 ) 2023年3月

Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease. 査読有り国際誌

Kawamura T, Yamamura T, Nakamura M, Maeda K, Sawada T, Ishikawa E, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M

Inflammatory bowel diseases 29 巻 ( 2 ) 頁： 245 - 253 2023年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Inflammatory bowel diseases

BACKGROUND: Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of treatment for Crohn's disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum biomarker correlated with disease activity in inflammatory bowel disease. However, studies evaluating its relationship with CD, particularly in the context of small intestinal lesions, are scarce. The aim of this study was to investigate the accuracy of LRG in assessing endoscopic activity, especially remission, in patients with CD. METHODS: Between July 2020 and March 2021, 72 patients with CD who underwent LRG testing and double-balloon endoscopy at the same time were included. Endoscopic activity was evaluated using the applied Simple Endoscopic Score for Crohn's disease, including small intestine lesions. The relationship of LRG with clinical symptoms and endoscopic activity was assessed, and its predictive accuracy was evaluated. RESULTS: Leucine-rich alpha-2 glycoprotein showed a significant positive correlation with endoscopic activity (r = 0.619, P < .001), even in patients with active lesions in the small intestine (r = 0.626, P < .001). Multivariate logistic regression revealed that LRG was the only factor associated with endoscopic remission. An LRG cutoff value of 8.9 μg/mL had a sensitivity of 93.3%; specificity of 83.3%; positive predictive value of 96.6%; negative predictive value of 71.4%; accuracy of 91.7%; and area under the curve of 0.904 for the prediction of endoscopic remission. CONCLUSIONS: Leucine-rich alpha-2 glycoprotein can be used in assessing endoscopic activity and is a reliable marker of endoscopic remission in CD patients. It can be an intermediate target in the treatment of CD.

DOI： 10.1093/ibd/izac076

Scopus

PubMed

Endoscopic injection sclerotherapy with polidocanol for cardiac varices in children and adolescents. 査読有り国際誌

Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Hinoki A, Sumida W, Shirota C, Tainaka T, Makita S, Yokota K, Uchida H, Ishigami M

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 30 巻 ( 2 ) 頁： 109 - 112 2023年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Archives de Pediatrie

Background: Like esophageal varices, cardiac varices are often treated with endoscopic variceal ligation (EVL). However, we previously reported that EVL for cardiac varices may be associated with a high risk of rebleeding from the ulcer if the O-ring spontaneously drops off early. The efficacy and safety of para-variceal endoscopic injection sclerotherapy (EIS) with polidocanol for the treatment of cardiac varices in children and adolescents were evaluated. Methods: Eleven patients under 18 years of age with portal hypertension who underwent para-variceal EIS with polidocanol for cardiac varices with red signs, which were considered to be at high risk of bleeding, were retrospectively reviewed. Results: One session of para-variceal polidocanol-EIS was performed for each of the 11 patients. One patient experienced temporary hypoxia due to aspiration of saliva when the tracheal intubation tube was removed after the procedure but recovered by endotracheal suctioning; there were no other adverse events. In six of the eight cases in which efficacy could be evaluated, eradication of cardiac varices was achieved. Conclusion: Para-variceal polidocanol-EIS may be considered instead of EVL for small cardiac varices with red signs in pediatric patients with cardiac varices.

DOI： 10.1016/j.arcped.2022.11.016

Scopus

PubMed

Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury. 査読有り国際誌

Yamamoto T, Morooka H, Ito T, Ishigami M, Mizuno K, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Yokota K, Hase T, Maeda O, Hashimoto N, Ando Y, Akiyama M, Kawashima H

Journal of gastroenterology and hepatology 38 巻 ( 2 ) 頁： 251 - 258 2023年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Gastroenterology and Hepatology (Australia)

Background and Aim: Immune-related liver injury (liver-irAE) is a clinical problem with a potentially poor prognosis. Methods: We retrospectively collected clinical data from patients treated with immune checkpoint inhibitors between September 2014 and December 2021 at the Nagoya University Hospital. Using an unsupervised machine learning method, the Gaussian mixture model, to divide the cohort into clusters based on inflammatory markers, we investigated the cumulative incidence of liver-irAEs in these clusters. Results: This study included a total of 702 patients. Among them, 492 (70.1%) patients were male, and the mean age was 66.6 years. During the mean follow-up period of 423 days, severe liver-irAEs (Common Terminology Criteria for Adverse Events grade ≥ 3) occurred in 43 patients. Patients were divided into five clusters (a, b, c, d, and e). The cumulative incidence of liver-irAE was higher in cluster c than in cluster a (hazard ratio [HR]: 13.59, 95% confidence interval [CI]: 1.70–108.76, P = 0.014), and overall survival was worse in clusters c and d than in cluster a (HR: 2.83, 95% CI: 1.77–4.50, P < 0.001; HR: 2.87, 95% CI: 1.47–5.60, P = 0.002, respectively). Clusters c and d were characterized by high temperature, C-reactive protein, platelets, and low albumin. However, there were differences in the prevalence of neutrophil count, neutrophil-to-lymphocyte ratio, and liver metastases between both clusters. Conclusions: The combined assessment of multiple markers and body temperature may help stratify high-risk groups for developing liver-irAE.

DOI： 10.1111/jgh.16038

Scopus

PubMed

Significance of pretreatment alpha-fetoprotein in patients with compensated severe fibrosis after hepatitis C viral eradication. 査読有り国際誌

Ishigami M, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Kawashima H

Journal of hepato-biliary-pancreatic sciences 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Hepato-Biliary-Pancreatic Sciences

Background: We aimed to investigate the factors associated with improvement of liver functional reserve after sustained virological response using interferon-free, direct-acting antiviral combination treatment in patients with compensated, severe fibrosis. Methods: Between September 2014 and April 2020, 492 patients received direct-acting antiviral combination treatment in our hospital. Among them, 173 patients who had severe fibrosis based on a fibrosis-4 index ≥3.25, showed sustained virological response after treatment. We investigated the dynamic change in albumin-bilirubin score and the baseline factors associated with its improvement, 48 weeks after treatment. Results: The baseline significant factors associated with albumin-bilirubin ≦ −0.5 were lower albumin (HR: 15.625, 95% CI: 4.273–58.824, P <.001), higher hepatitis C virus RNA (HR: 4.995, 95% CI: 1.882–13.260, P =.001), and higher alpha-fetoprotein (HR: 1.033, 95% CI: 1.011–1.055, P =.003). Patients with alpha-fetoprotein ≧10 ng/mL showed significant improvement of albumin-bilirubin score from baseline to 48 weeks after treatment compared to those with alpha-fetoprotein <10 ng/mL (P <.001). Conclusions: Baseline serum alpha-fetoprotein might be a predictive factor for improvement of liver function after sustained virological response in patients with severe fibrosis.

DOI： 10.1002/jhbp.1309

Scopus

PubMed

CO(2) enterography in endoscopic retrograde cholangiography using double-balloon endoscopy: A randomized clinical trial. 査読有り国際誌

Murate K, Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Kida Y, Esaki M, Hamazaki M, Iida T, Mizutani Y, Yamao K, Ishikawa T, Furukawa K, Ohno E, Honda T, Ishigami M, Kinoshita F, Ando M, Kawashima H

Journal of gastroenterology and hepatology 2023年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Gastroenterology and Hepatology (Australia)

Background and Aim: Double-balloon endoscopic retrograde cholangiography (DBERC) is a valuable procedure for patients with altered gastrointestinal anatomy. Nonetheless, it is time-consuming and burdensome for both patients and endoscopists, partly because route selection in the reconstructed bowel with complicating loop is challenging. Carbon dioxide insufflation enterography is reportedly useful for route selection in the blind loop. This prospective randomized clinical trial investigated the usefulness of carbon dioxide insufflation enterography for route selection by comparing it with conventional observation. Methods: Patients scheduled to undergo DBERC were consecutively registered. They were divided into carbon dioxide insufflation enterography and conventional groups via randomization according to stratification factors, type of reconstruction methods, and experience with DBERC. The primary endpoint was the correct rate of initial route selection. The secondary endpoints were the insertion time, examination time, amount of anesthesia drugs, and complications. Results: The correct rate of route selection was significantly higher in the carbon dioxide insufflation enterography group (23/25, 92%) than in the visual method (15/25, 60%) (P = 0.018). The insertion time was significantly shorter in the carbon dioxide insufflation enterography group than in the visual group (10.8 ± 11.1 min vs 29.8 ± 15.7 min; P < 0.001). No significant differences in complications were noted between the two groups. The amounts of sedatives and analgesics used were significantly lower in the carbon dioxide insufflation enterography group (P < 0.001 and P < 0.001, respectively). Conclusions: Carbon dioxide insufflation enterography can reduce the burden of DBERC on patients and endoscopists by shortening the examination time and reducing the amount of medication.

DOI： 10.1111/jgh.16112

Scopus

PubMed

*Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study. 査読有り国際誌

Shuji Ikegami, Masanao Nakamura, Takashi Honda, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kenta Yamamoto, Satoshi Furune, Takuya Ishikawa, Kazuhiro Furukawa, Eizaburo Ohno, Masatoshi Ishigami, Fumie Kinoshita, Yoshihiro Kadota, Takumi Tochio, Yoshiharu Shimomura, Yoshiki Hirooka, Hiroki Kawashima

Alimentary pharmacology & therapeutics 2023年1月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Ulcerative colitis involves an excessive immune response to intestinal bacteria. Whether administering prebiotic 1-kestose is effective for active ulcerative colitis remains controversial. AIMS: This randomised, double-blind, placebo-controlled pilot trial investigated the efficacy of 1-kestose against active ulcerative colitis. METHODS: Forty patients with mild to moderate active ulcerative colitis were randomly treated with 1-kestose (N = 20) or placebo (maltose, N = 20) orally for 8 weeks in addition to the standard treatment. The Lichtiger clinical activity index and Ulcerative Colitis Endoscopic Index of Severity were determined. Faecal samples were analysed to evaluate the gut microbiome and metabolites. RESULTS: The clinical activity index at week 8 was significantly lower in the 1-kestose group than in the placebo group (3.8 ± 2.7 vs. 5.6 ± 2.1, p = 0.026). Clinical remission and response rates were higher in the 1-kestose group than in the placebo group (remission: 55% vs. 20%, p = 0.048; response: 60% vs. 25%, p = 0.054). The Ulcerative Colitis Endoscopic Index of Severity at week 8 was not significantly different (2.8 ± 1.6 vs. 3.5 ± 1.6, p = 0.145). Faecal analysis showed significantly reduced alpha-diversity in the 1-kestose group, with a decreased relative abundance of several bacteria, including Ruminococcus gnavus group. The short-chain fatty acid levels were not significantly different between the groups. The incidence of adverse events was comparable between the groups. DISCUSSION: Oral 1-kestose is well tolerated and provides clinical improvement for patients with mild to moderate ulcerative colitis through modulation of the gut microbiome.

DOI： 10.1111/apt.17387

Scopus

PubMed

*Astaxanthin Attenuates Nonalcoholic Steatohepatitis with Downregulation of Osteoprotegerin in Ovariectomized Mice Fed Choline-Deficient High-Fat Diet 査読有り国際誌

Meng Zhao, Lingyun Ma, Takashi Honda, Asuka Kato, Taichi Ohshiro, Shinya Yokoyama, Kenta Yamamoto, Takanori Ito, Norihiro Imai, Yoji Ishizu, Masanao Nakamura, Hiroki Kawashima, Noriko M. Tsuji, Masatoshi Ishigami, Mitsuhiro Fujishiro

Digestive Diseases and Sciences 68 巻 ( 1 ) 頁： 155 - 163 2023年1月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

DOI： 10.1007/s10620-022-07489-6

Scopus

PubMed

CiNii Research

その他リンク： https://link.springer.com/article/10.1007/s10620-022-07489-6/fulltext.html

Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8(+) T cell quality. 査読有り国際誌

Takahama S, Yoshio S, Masuta Y, Murakami H, Sakamori R, Kaneko S, Honda T, Murakawa M, Sugiyama M, Kurosaki M, Asahina Y, Takehara T, Appay V, Kanto T, Yamamoto T

Frontiers in immunology 14 巻頁： 1257113 2023年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Frontiers in Immunology

Despite treatment, hepatitis B surface antigen (HBsAg) persists in patients with chronic hepatitis B (CHB), suggesting the likely presence of the virus in the body. CD8+ T cell responses are essential for managing viral replication, but their effect on HBsAg levels remains unclear. We studied the traits of activated CD8+ T cells and HBV-specific CD8+ T cells in the blood of CHB patients undergoing nucleos(t)ide analog (NUC) therapy. For the transcriptome profiling of activated CD8+ T cells in peripheral blood mononuclear cells (PBMCs), CD69+ CD8+ T cells were sorted from six donors, and single-cell RNA sequencing (scRNA-seq) analysis was performed. To detect HBV-specific CD8+ T cells, we stimulated PBMCs from 26 donors with overlapping peptides covering the HBs, HBcore, and HBpol regions of genotype A/B/C viruses, cultured for 10 days, and analyzed via multicolor flow cytometry. scRNA-seq data revealed that CD8+ T cell clusters harboring the transcripts involved in the cytolytic functions were frequently observed in donors with high HBsAg levels. Polyfunctional analysis of HBV-specific CD8+ T cells utilized by IFN-γ/TNFα/CD107A/CD137 revealed that HBcore-specific cells exhibited greater polyfunctionality, suggesting that the quality of HBV-specific CD8+ T cells varies among antigens. Moreover, a subset of HBcore-specific CD8+ T cells with lower cytolytic potential was inversely correlated with HBsAg level. Our results revealed a stimulant-dependent qualitative difference in HBV-specific CD8+ T cells in patients with CHB undergoing NUC therapy. Hence, the induction of HBcore-specific CD8+ T cells with lower cytolytic potential could be a new target for reducing HBsAg levels.

DOI： 10.3389/fimmu.2023.1257113

Scopus

PubMed

The presence of high-risk varices after sclerotherapy in biliary atresia. 査読有り国際誌

Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Shirota C, Tainaka T, Sumida W, Makita S, Takimoto A, Nakagawa Y, Takada S, Ishigami M, Uchida H, Kawashima H

Pediatrics international : official journal of the Japan Pediatric Society 頁： e15454 2022年12月

Pipeline Esophagogastric Varices Secondary to Extrahepatic Portal Vein Obstruction Treated Endoscopically with the Assistance of Transileocolic Obliteration. 査読有り国際誌

Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Komada T, Hayashi M, Ishigami M

Internal medicine (Tokyo, Japan) 61 巻 ( 23 ) 頁： 3503 - 3511 2022年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本内科学会

Endoscopic injection sclerotherapy (EIS) for esophagogastric varices (EGV) was attempted for a 29-yearold man with extrahepatic portal vein obstruction. However, pipeline varices characterized by a large blood flow volume were present, and the sclerosant did not accumulate sufficiently in them. Transileocolic obliteration (TIO) using coils was performed, but some EGVs and palisading veins remained. Thus, EIS was performed once again immediately after TIO. Since a reduction in the intravariceal blood flow was achieved by preceding TIO, effective injection of sclerosant into the vessels was possible. For pipeline varices difficult to treat endoscopically, combination therapy with TIO may be effective.

DOI： 10.2169/internalmedicine.9404-22

Scopus

PubMed

CiNii Research

The effects of ustekinumab on small intestinal lesions and stenotic lesions. 査読有り国際誌

Wada H, Murate K, Nakamura M, Furukawa K, Kakushima N, Yamamura T, Maeda K, Sawada T, Ishikawa E, Ishikawa T, Ohno E, Honda T, Kawashima H, Nakayama G, Hattori N, Umeda S, Ishigami M

Nagoya journal of medical science 84 巻 ( 4 ) 頁： 825 - 838 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nagoya Journal of Medical Science

Crohn’s disease patients suffer from symptoms originating from small bowel lesions, including strictures. As many of these patients also have a potential risk of surgery, it is important to consider various therapeutic strategies for small bowel lesions. We retrospectively analyzed the therapeutic effects of ustekinumab, interleukin-12 and -23 blocker, for small intestinal lesions and intestinal stenosis in order to contribute to the optimal management of Crohn’s disease. Patients who underwent total colonoscopy or small bowel endoscopy before and after the introduction of ustekinumab were enrolled in this study. The colonoscopy findings were evaluated by the simple endoscopic score for Crohn’s disease, and small bowel endoscopy findings were evaluated using the modified simple endoscopic score for Crohn’s disease. Endoscopic scores were compared before and after the introduction of ustekinumab and between the responders and non-responders to ustekinumab. Responders were defined as those whose Crohn’s disease activity index score at 24 weeks fell below 150 points, or those whose score decreased by more than 100 points from the pre-induction level. A total of 50 patients were enrolled in the study, and the number of responders was 35. Pre-induction simple endoscopic scores were lower for responders, but no significant difference was observed in the modified simple endoscopic scores. The total decrease in the endoscopic score was significantly higher in the responders for both the small and large intestine. Use of ustekinumab as a first-line treatment for patients with small bowel lesions or stricture-prone lesions may be a new treatment consideration in the future.

DOI： 10.18999/nagjms.84.4.825

Scopus

PubMed

Factors associated with the progression of myosteatosis in patients with cirrhosis. 査読有り国際誌

Ishizu Y, Ishigami M, Honda T, Imai N, Ito T, Yamamoto K, Yokoyama S, Ishikawa T, Fujishiro M

Nutrition (Burbank, Los Angeles County, Calif.) 103-104 巻頁： 111777 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nutrition

Objectives: The presence of myosteatosis is one factor associated with poor prognosis for patients with cirrhosis; however, the factors contributing to worsening myosteatosis are, to our knowledge, unknown. The aim of this study was to clarify the changes in myosteatosis, and the factors involved in these changes. Methods: The present study enrolled 178 patients with cirrhosis who underwent computed tomography twice to measure changes in skeletal muscle attenuation (SMA) at the L3 level. Factors associated with SMA and those associated with changes in SMA were examined. Results: Using linear multiple regression analysis, age (β = –0.22), skeletal muscle index (SMI; skeletal muscle area divided by height squared; β = 0.25), and visceral and subcutaneous fat indices (VFI and SFI; the visceral and subcutaneous fat areas at the umbilical level divided by height squared; β = –0.08, β = –0.06, respectively) were identified as associated with SMA. The 100-d change in SMA was –0.21 ± 1.29 Hounsfield units (HU). Changes in SMI and SMA were positively associated (R = 0.183, P = 0.014), whereas those in VFI and SMA were negatively associated (R = –0.172, P = 0.022). No association was noted between the 100-d changes in SFI and SMA. In patients whose SMI increased and VFI decreased, the 100-d change in SMA was 0.24 ± 1.82 HU, which was marginally different from that in patients whose SMI decreased and VFI increased (–0.44 ± 1.32 HU, P = 0.077). Conclusions: In patients with cirrhosis, myosteatosis progressed, and decreases in SMI and increases in VFI were correlated with its progression.

DOI： 10.1016/j.nut.2022.111777

Scopus

PubMed

Effect of illness uncertainty on alanine transaminase levels and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease. 査読有り国際誌

Ozawa N, Sato K, Sugimura A, Maki S, Tanaka T, Yamamoto K, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Fujishiro M, Ishikawa T, Ando S

Nagoya journal of medical science 84 巻 ( 4 ) 頁： 857 - 864 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nagoya Journal of Medical Science

Patients with nonalcoholic fatty liver disease (NAFLD) have illness uncertainty. The purpose of this longitudinal study was to investigate the effect of the degree of illness uncertainty in patients with NAFLD on liver function values. We conducted a questionnaire survey and collected blood samples from outpatients with NAFLD. The items in the questionnaire were measured for illness uncertainty using the Japanese version of the Mishel Uncertainty in Illness Scale-Community (MUIS-C). Blood samples were collected at baseline and after 1 year. We divided the patients into two groups: one with high illness uncertainty and the other with low illness uncertainty. We then compared changes in alanine transaminase (ALT) and aspartate aminotransferase (AST) levels over time from baseline using multiple regression analysis. This study analyzed 148 patients with NAFLD; 75 were male and 73 were female, with a mean age of 58.4 ± 12.3 years. The group with higher illness uncertainty had significantly higher ALT and AST levels at 1 year (b =.185 and.183, respectively) than the group with lower illness uncertainty. High illness uncertainty in patients with NAFLD can lead to higher ALT and AST levels. Healthcare providers must focus on reducing illness uncertainty in patients with NAFLD.

DOI： 10.18999/nagjms.84.4.857

Web of Science

Scopus

PubMed

Decreased appetite is associated with the presence of sarcopenia in patients with cirrhosis. 査読有り国際誌

Ishizu Y, Ishigami M, Honda T, Imai N, Ito T, Yamamoto K, Yokoyama S, Ishikawa T, Kawashima H

Nutrition (Burbank, Los Angeles County, Calif.) 103-104 巻頁： 111807 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nutrition

Objectives: To our knowledge, the relationship between appetite and sarcopenia in patients with cirrhosis is unknown. The aims of this study were to examine the factors associated with decreased appetite and to clarify the relationship between appetite and sarcopenia. Methods: This study included 61 patients with cirrhosis. The patients were asked to describe their appetite using a numerical rating scale (NRS) from 0 (none at all) to 10 (most), with ≤5 defined as decreased appetite. The clinical characteristics, gastrointestinal symptoms as assessed using the Gastrointestinal Symptom Rating Scale, handgrip strength, and skeletal muscle area at the third vertebra were collected retrospectively. Sarcopenia was diagnosed according to the criteria of the Japan Society of Hepatology. The differences in these factors between patients with and without decreased appetite, and the factors associated with the presence of sarcopenia were examined. Results: Alcoholic liver disease was the most common etiology. The median Model for End-Stage Liver Disease score was 8 (interquartile range = 7 - 10) and hepatocellular carcinoma was present in 35 patients. Overall, 36% of the patients with cirrhosis had decreased appetite. Patients with decreased appetite had a higher frequency of abdominal pain and acid reflux–related symptoms and significantly lower handgrip strength than patients without, among both men (P = 0.034) and women (P = 0.017). The multivariate analysis identified a decrease in appetite as a significant factor associated with the presence of sarcopenia (NRS one increase, odds ratio, 0.701; 95% confidence interval, 0.502–0.977; P = 0.036). Conclusion: Decreased appetite was associated with the presence of sarcopenia.

DOI： 10.1016/j.nut.2022.111807

Scopus

PubMed

Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases. 査読有り国際誌

Rodríguez Meza MR, Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Kakushima N, Furukawa K, Iida T, Mizutani Y, Ishikawa T, Ohno E, Honda T, Kawashima H, Ishigami M

Nagoya journal of medical science 84 巻 ( 4 ) 頁： 733 - 745 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Nagoya Journal of Medical Science

There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease.

DOI： 10.18999/nagjms.84.4.733

Scopus

PubMed

An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images. 査読有り国際誌

Sugiyama Y, Ishizu Y, Ando Y, Yokoyama S, Yamamoto K, Ito T, Imai N, Nakamura M, Honda T, Kawashima H, Ishikawa T, Ishigami M

Hepatology research : the official journal of the Japan Society of Hepatology 52 巻 ( 11 ) 頁： 937 - 946 2022年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Hepatology Research

Aim: Conventionally, the skeletal muscle area with computed tomography (CT) attenuation ranging from −29 to +150 Hounsfield unit (HU) divided by height squared (the conventional skeletal muscle index [SMI]) was used as an index of skeletal muscle mass. However, it includes fat-infiltrated skeletal muscle, which is known to have poor function. This study aims to determine whether the low-fat SMI, which uses skeletal muscle mass with CT attenuation ranging from +30 to +150 HU, or conventional SMI appropriately reflects the function of skeletal muscle. Methods: We retrospectively analyzed 120 patients with cirrhosis whose handgrip strength was measured. Among them, 48 patients underwent a physical performance assessment such as liver frailty index (LFI) and short physical performance battery (SPPB), and 80 underwent quality of life (QOL) assessment. The relationships between each SMI and handgrip strength, LFI, SPPB, and QOL were evaluated. Results: Low-fat SMI was significantly correlated with handgrip strength (males, R = 0.393, p = 0.002; females, R = 0.423, p < 0.001) and LFI (males, R = −0.535, p = 0.035; females, R = −0.368, p = 0.039), whereas conventional SMI was not. When using low-fat SMI, patients with low skeletal muscle mass had significantly low handgrip strength, LFI, SPPB, and physical and social-related QOL score than those without. By contrast, no significant differences were found for any items when using conventional SMI. Conclusions: Low-fat SMI is a good index of skeletal muscle mass that appropriately reflects skeletal muscle function.

DOI： 10.1111/hepr.13820

Scopus

PubMed

Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma. 査読有り国際誌

Imai N, Ishigami M, Oie Y, Kumagai M, Inukai Y, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kawashima H

Anticancer research 42 巻 ( 8 ) 頁： 3947 - 3951 2022年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Anticancer Research

Background/Aim: A porous glass membrane-pumping emulsification device (GMD) enables the formation of a high-percentage water-in-oil emulsion with homogeneous and stable droplets. Although GMD is expected to improve the locoregional therapeutic effects of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC), its effectiveness in the management of solitary HCC remains unclear. Patients and Methods: Patients treated for solitary HCCs (<5 cm) were retrospectively reviewed. A total of 46 patients who could not undergo liver resection and were unsuitable for radiofrequency ablation were included in this study. Among these, 22 patients underwent TACE using a GMD (GMD-TACE group) and 24 underwent stereotactic body radiotherapy (SBRT) using a robotic radiosurgery system (SBRT group). Local control rates were compared between the two groups. Results: The median HCC tumour size was 24 mm (range=12-50 mm) and 22 mm (range=8-39 mm) in the GMD-TACE and SBRT groups, respectively; however, the difference between the groups was not significant. Age, liver function test results, or Child-Pugh scores were not significantly different between the two groups. The rate of local control at 6 months after treatment was 100% in both groups. Although the 1-year local control rate was higher in the SBRT group (92.3%) than in the GMD-TACE group (81.8%), there was no significant difference in the log-rank test (p=0.654). No major treatment-related complications occurred in either group during the observation period. Conclusion: TACE with GMD could be considered an effective treatment option for the management of solitary HCC.

DOI： 10.21873/anticanres.15889

Scopus

PubMed

Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan. 査読有り国際誌

Hamazaki M, Sawada T, Yamamura T, Maeda K, Mizutani Y, Ishikawa E, Furune S, Yamamoto K, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Nakamura M, Fujishiro M

BMC gastroenterology 22 巻 ( 1 ) 頁： 342 2022年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BMC Gastroenterology

Background: Fecal microbiota transplantation (FMT) is a potential treatment for irritable bowel syndrome (IBS), but its efficacy in Japanese IBS patients is unknown. This study aimed to evaluate the efficacy, side effects, and microbiome changes following FMT in Japanese IBS patients. Methods: Seventeen Japanese patients with refractory IBS received FMT (4 donors) under colonoscopy. Responders were defined by an improvement in the IBS severity index (IBS-SI) of 50 points or more after 12 weeks. We evaluated the IBS-SI and Bristol Stool Form Scale (BSFS) and compared the diversity and microbiome before and 12 weeks after FMT. For the microbiome, we analyzed the V3–V4 region of the 16S rRNA gene. Results: IBS-SI decreased an average of 115.58 points after 12 weeks, and 10 patients (58.8%) were considered responders. Eight patients with diarrhea (66.7%) and three patients with constipation (60.0%) showed improvement in the BSFS. Two patients complained of mild abdominal pain, but there were no cases with severe side-effects. α-diversity was increased only in the responder group (p = 0.017). Patients who closely paralleled the donor microbiome had a higher rate of IBS-SI improvement. The relative abundance of Neisseria and Akkermansia increased and Desulfovibrio and Delftia were decreased in the responder group after FMT. Conclusions: Following FMT, about 60% of Japanese patients with IBS showed improvement in both the IBS-SI and BSFS, without severe side effects. Increased α-diversity and similarity to the donor microbiome after FMT may be associated with better treatment effects. Trial registration: This study was registered in the University Hospital Medical Information Network Clinical Trial Registration (UMIN000026363). Registered 31 May 2017, https://rctportal.niph.go.jp/s/detail/um?trial_id=UMIN000026363. The study was registered prospectively.

DOI： 10.1186/s12876-022-02408-5

Scopus

PubMed

Endoscopic sphincterotomy and endoscopic biliary stenting do not affect the sensitivity of transpapillary forceps biopsy for the diagnosis of bile duct adenocarcinoma. 査読有り国際誌

Aoki T, Ohno E, Ishikawa T, Mizutani Y, Iida T, Yamao K, Yamamura T, Furukawa K, Nakamura M, Honda T, Ishigami M, Yatsuya H, Kawashima H

BMC gastroenterology 22 巻 ( 1 ) 頁： 329 2022年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BMC Gastroenterology

Background: The pathological evaluation of tissues with cholangitis is considered difficult, which can often occur after endoscopic sphincterotomy (EST) and endoscopic biliary stenting (EBS). This study aimed to evaluate the influence of a history of EST and EBS on the sensitivity of transpapillary forceps bile duct biopsy (TB) for bile duct adenocarcinoma. Methods: This retrospective study included consecutive cases of bile duct adenocarcinoma in which TB was performed before July 2020 until the number exceeded that required to support statistical and noninferiority analyses of the sensitivity of TB between patients with and without each variable. The incidence of postprocedural adverse events related to each factor was also investigated. Results: Overall, 280 samples were required in each group, and 437 subjects (792 samples) were included. The sensitivity of TB was 63.6% for the subjects and 59.6% for the biopsy samples. For the biopsy samples, the sensitivity did not differ significantly between samples from patients with and without a history of EST (59.1% vs. 58.9%, P = 0.952) and EBS (62.1% vs. 55.4%, P = 0.065). The sensitivity was significantly higher for samples from patients with jaundice (67.9% vs. 57.0%, P = 0.008). There were significantly fewer procedure-related adverse events in patients with a history of EST (10.8% vs. 19.0%, P = 0.017) and EBS (12.0% vs. 21.7%, P = 0.005). Conclusions: A history of EST or EBS did not influence sensitivity of TB but significantly decreased the incidence of adverse events. To safely and reliably perform TB to diagnose bile duct adenocarcinoma, planning, including for EST and EBS, is necessary.

DOI： 10.1186/s12876-022-02402-x

Scopus

PubMed

A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis. 査読有り国際誌

Yamamoto T, Ito T, Mizuno K, Shinya Y, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Matsui T, Hase T, Hashimoto N, Ishigami M

Journal of digestive diseases 23 巻 ( 7 ) 頁： 404 - 409 2022年7月

Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis. 査読有り国際誌

Maeda K, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Oishi A, Ikegami S, Kakushima N, Furukawa K, Iida T, Mizutani Y, Ishikawa T, Ohno E, Honda T, Ishigami M, Kawashima H

Biomedicines 10 巻 ( 4 ) 2022年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Biomedicines

The therapeutic goal in ulcerative colitis is mucosal healing, which requires improved non-invasive biomarkers to evaluate disease activity. Gelsolin is associated with several autoimmune diseases, and here, we aimed to analyze its usefulness as a serological biomarker for clinical and endoscopic activities in ulcerative colitis. Patients with ulcerative colitis (n = 138) who had undergone blood tests and colonoscopy were included. Serum gelsolin was measured using enzyme-linked immunosorbent assay, and correlation between the gelsolin level and clinical and endoscopic activities was examined. The serum gelsolin level in patients with ulcerative colitis was significantly lower than that in healthy subjects, and it decreased in proportion to increasing Mayo score and Mayo endoscopic subscore. The area under the curve for correlation between clinical and endoscopic remission and serum gelsolin level was higher than that for C-reactive protein. Furthermore, in C-reactive protein-negative patients, the serum gelsolin level was lower in the active phase than in remission. Our findings indicate that the serum gelsolin level correlates with clinical and endoscopic activities in ulcerative colitis, has a higher sensitivity and specificity than C-reactive protein, and can detect mucosal healing, suggesting that gelsolin can be used as a biomarker for ulcerative colitis.

DOI： 10.3390/biomedicines10040872

Scopus

PubMed

CiNii Research

*Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma 査読有り国際誌

Inukai Y, Yamamoto K, Honda T*, Ito T, Imai N, Ishizu Y, Nakamura M, Kawashima H, Ishigami M.

Dig Dis. 2022年3月

Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study. 査読有り国際誌

Yamamoto T, Imai N, Kuzuya T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M

Nutrition and cancer 頁： 1 - 10 2022年3月

*Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease. 査読有り国際誌

Yamamoto K, Ishizu Y, Honda T*, Ito T, Imai N, Nakamura M, Kawashima H, Kitaura Y, Ishigami M, Fujishiro M

Scientific reports 12 巻 ( 1 ) 頁： 3674 2022年3月

担当区分：責任著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Scientific Reports

Sarcopenia is thought to be related to the microbiome, but not enough reports in chronic liver disease (CLD) patients. In addition to the differences in microbiome, the role of the microbiome in the gut is also important to be clarified because it has recently been shown that the microbiome may produce branched-chain amino acids (BCAAs) in the body. In this single-center study, sixty-nine CLD patients were divided by skeletal muscle mass index (SMI) into low (L-SMI: n = 25) and normal (N-SMI: n = 44). Microbiome was analyzed from stool samples based on V3-4 region of bacterial 16S rRNA). L-SMI had a lower Firmicutes/Bacteroidetes ratio than N-SMI. At the genus level, Coprobacillus, Catenibacterium and Clostridium were also lower while the Bacteroides was higher. Predictive functional profiling of the L-SMI group showed that genes related to nitrogen metabolism were enriched, but those related to amino acid metabolism, including BCAA biosynthesis, were lower. The genes related to 'LPS biosynthesis' was also higher. The microbiome of CLD patients with low muscle mass is characterized not only by high relative abundance of gram-negative bacteria with LPS, but also by the possibility of low potential for amino acid synthesis including BCAAs.

DOI： 10.1038/s41598-022-07810-3

Scopus

PubMed

Network Analysis of Gut Microbiota Including Fusobacterium and Oral Origin Bacteria and Their Distribution on Tumor Surface, Normal Mucosa, and in Feces in Patients with Colorectal Cancer. 査読有り国際誌

Ohashi A, Yamamura T, Nakamura M, Maeda K, Sawada T, Ishikawa E, Yamamoto K, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

Digestion 103 巻 ( 6 ) 頁： 451 - 461 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Digestion

Introduction: Fusobacterium and several bacteria are reported to be associated with colorectal cancer (CRC). However, their relationship and whether they cause CRC or are just adapted to the cancerous environment is not known. We approached this subject by investigating the correlation and distribution of the bacteria throughout the colon in patients with CRC and elucidated the relationship between microbiota and CRC. Methods: Twenty-five patients with CRC who underwent colonoscopy for endoscopic submucosal dissection or surgery were prospectively enrolled. Fecal samples were taken before bowel preparation, and mucosal samples were collected from three sites (tumor surface, tumor-adjacent mucosa, and cecum) during colonoscopy using a cytology brush. The microbiota was identified and analyzed by sequencing of the 16S rRNA gene of the V3-V4 region. We evaluated the correlation between the bacteria based on network analysis and the distribution of Fusobacterium in the colon. Results: A network consisting of many bacteria was found in all sites; especially, oral origin bacteria including Fusobacterium formed a positively correlated network on tumor surface. Streptococcus showed a significantly higher relative abundance on tumor surface than in feces. The relative abundance of Fusobacterium had significant positive correlations between tumor surface and feces, tumor-adjacent mucosa, and cecum. Conclusion: In patients with CRC, many bacteria were correlated with each other, and Fusobacterium and oral origin bacteria formed a positively correlated network on tumor surface. Fusobacterium was equally distributed on tumor surface and throughout the lumen and mucus in the colon. In the colon where Fusobacterium is widely distributed, Fusobacterium would adhere to the tumor surface and be correlated with oral origin bacteria to make a microenvironment that is favorable for CRC.

DOI： 10.1159/000527170

Scopus

PubMed

Comparison of Endoscopic Ultrasonography and Conventional Endoscopy for Prediction of Tumor Depth in Superficial Nonampullary Duodenal Epithelial Tumors. 査読有り国際誌

Matsuda N, Hirose T, Kakushima N, Furukawa K, Furune S, Ishikawa E, Sawada T, Maeda K, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Honda T, Ishigami M, Kawashima H, Fujishiro M

Digestion 103 巻 ( 4 ) 頁： 319 - 328 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Digestion

Background: The utility of endoscopic ultrasonography (EUS) in predicting tumor depth among superficial nonampullary duodenal epithelial tumors (SNADETs) is unclear. The aim was to compare EUS with conventional endoscopy (CE) for the evaluation of tumor invasion of SNADETs. Methods: A retrospective analysis was performed on consecutive 174 lesions/169 patients with duodenal dysplasia or adenocarcinoma with invasion up to submucosa who underwent both CE and EUS before endoscopic (n = 133) or surgical (n = 41) treatment. Endoscopic staging by CE was performed based on the characteristic endoscopic criteria of submucosal invasion (irregular surface, submucosal tumor [SMT]-like marginal elevation, and fusion of converging folds). The diagnostic performance of each test was compared with the final histology. Results: The sensitivity and accuracy of estimating the depth were higher for CE compared to that of EUS (99.4% vs. 89.4%, p < 0.01 and 97.7% vs. 87.9%, p < 0.01, respectively). Univariate analysis of endoscopic factors revealed that tumor diameter, red color, SMT-like appearance, and hypoechogenicity were factors related to advanced histology. Multivariate analysis revealed that the presence of SMT-like appearance based on CE was an independent factor to predict submucosal invasion (p = 0.025). Gross morphology of the combined type was associated to incorrect diagnosis of EUS (p = 0.007). Among 3 cases in which EUS overestimated the tumor depth, carcinoma extension in submucosal Brunner's gland or nontumorous submucosal cystic dilation was observed. Conclusion: EUS may not be necessary, and CE may be sufficient for determining the optimal therapeutic strategy for SNADETs.

DOI： 10.1159/000524841

Scopus

PubMed

*Changes in the gut microbiota after hepatitis C virus eradication 査読有り国際誌

Honda T, Ishigami M, Yamamoto K, Takeyama T, Ito T, Ishizu, Y, Kuzuya T, Nakamura M, Kawashima H, Miyahara R, Tetsuya T, Yoshiki Hirooka Y, Fujishiro M

Scientific Reports 2021年12月

*Changes in the gut microbiome in relation to the degree of gastric mucosal atrophy before and after Helicobacter pylori eradication. 査読有り国際誌

Furune S, Yamamoto K, Honda T*, Fujiyoshi T, Kakushima N, Furukawa K, Ohno E, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Hirooka Y, Fujishiro M

Scandinavian journal of gastroenterology 頁： 1 - 8 2021年11月

*Microbiome, fibrosis and tumor networks in a non-alcoholic steatohepatitis model of a choline-deficient high-fat diet using diethylnitrosamine. 査読有り国際誌

Yamamoto K, Honda T*, Yokoyama S, Ma L, Kato A, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Kawashima H, Ishigami M, Tsuji NM, Fujishiro M

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 53 巻 ( 11 ) 頁： 1443 - 1450 2021年11月

*Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. 査読有り国際誌

Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T

Cellular and molecular gastroenterology and hepatology 12 巻 ( 5 ) 頁： 1583 - 1598 2021年8月

*The relationship between oral-origin bacteria in the fecal microbiome and albumin-bilirubin grade in patients with hepatitis C. 査読有り国際誌

Yamamoto K, Honda T*, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Fujishiro M

Journal of gastroenterology and hepatology 36 巻 ( 3 ) 頁： 790 - 799 2021年3月

*Influence of proton pump inhibitors on microbiota in chronic liver disease patients 査読有り国際誌

Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y.

Hepatology International 13 巻 ( 2 ) 頁： 234-244 2019年3月

*Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. 査読有り国際誌

Honda T, Ishigami M, Luo F, Lingyun M, Ishizu Y, Kuzuya T, Hayashi K, Nakano I, Ishikawa T, Feng GG, Katano Y, Kohama T, Kitaura Y, Shimomura Y, Goto H, Hirooka Y.

Metabolism. 69 巻頁： 177-187 2017年

*The Core I97L mutation in conjunction with P79Q is associated with persistent low HBVDNA and HBs antigen clearance in chronic hepatitis B patients 査読有り国際誌

Honda T, Ishigami M, Ishizu Y1, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, Kumada T, Katano Y, Goto H, Hirooka Y.

Clin Microbiol Infect. 23 巻 ( 407 ) 頁： e1-e7 2016年12月

*Effect of Peginterferon alfa-2b and Ribavirin on Hepatocellular Carcinoma Prevention in Older Patients with Chronic Hepatitis C 査読有り国際誌

Honda T, Ishigami M, Hayashi H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H.

J Gastroenterol Hepatol 30 巻 ( 2 ) 頁： 321 - 328 2015年2月

*Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders 査読有り国際誌

Honda T, Katano Y, Kuzuya T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Toyoda H, Kumada T, Yamamoto K, Matsushita T, Kojima T, Takamatsu J, Goto H.

J Med Virol. 85 巻 ( 2 ) 頁： 228 - 234 2013年2月

*Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years andolder with chronic hepatitis C. 査読有り国際誌

Honda T, Katano Y, Shimizu J, Ishizu Y, Doizaki M, Hayashi K, Ishigami M,Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 30 巻 ( 4 ) 頁： 527 - 537 2010年4月

*Efficacy of ribavirin plus Efficacy of ribavirin plus interferon-α in patients aged >or=60 years with chronic hepatitis C. 査読有り国際誌

Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H

J Gastroenterol Hepatol. 22 巻 ( 7 ) 頁： 989 - 995 2007年7月

*Ribavirin and use of clotting factors in patients with hemophilia and chronic hepatitis C 査読有り国際誌

Honda T, Toyoda H, Hayashi K, Katano Y, Yano M, Nakano I, Yoshioka K, Goto H, Yamamoto K, Takamatsu J

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 293 巻 ( 10 ) 頁： 1190 - 1192 2005年3月

*Effects of liver failure on branched-chain alpha-keto acid dehydrogenase complex in rat liver and muscle: comparison between acute and chronic liver failure 査読有り国際誌

Honda T, Fukuda Y, Nakano I, Katano Y, Goto H, Nagasaki M, Sato Y, Murakami T, Shimomura Y.

J Hepatol. 40 巻 ( 3 ) 頁： 439 - 445 2004年3月

JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease. 査読有り国際誌

Makita S, Yasu T, Akashi YJ, Adachi H, Izawa H, Ishihara S, Iso Y, Ohuchi H, Omiya K, Ohya Y, Okita K, Kimura Y, Koike A, Kohzuki M, Koba S, Sata M, Shimada K, Shimokawa T, Shiraishi H, Sumitomo N, Takahashi T, Takura T, Tsutsui H, Nagayama M, Hasegawa E, Fukumoto Y, Furukawa Y, Miura SI, Yasuda S, Yamada S, Yamada Y, Yumino D, Yoshida T, Adachi T, Ikegame T, Izawa KP, Ishida T, Ozasa N, Osada N, Obata H, Kakutani N, Kasahara Y, Kato M, Kamiya K, Kinugawa S, Kono Y, Kobayashi Y, Koyama T, Sase K, Sato S, Shibata T, Suzuki N, Tamaki D, Yamaoka-Tojo M, Nakanishi M, Nakane E, Nishizaki M, Higo T, Fujimi K, Honda T, Matsumoto Y, Matsumoto N, Miyawaki I, Murata M, Yagi S, Yanase M, Yamada M, Yokoyama M, Watanabe N, Itoh H, Kimura T, Kyo S, Goto Y, Nohara R, Hirata KI, Japanese Circulation Society/the Japanese Association of Cardiac Rehabilitation Joint Working Group

Circulation journal : official journal of the Japanese Circulation Society 87 巻 ( 1 ) 頁： 155 - 235 2022年12月

TWO DISTINCT ROLES OF LIPID DROPLETS INSIDE THE NUCLEUS IN LIVER DISEASES 査読有り国際誌

Imai, N; Cheng, JL; Tanaka, T; Yokoyama, S; Yamamoto, K; Ito, T; Ishizu, Y; Honda, T; Ishigami, M; Wake, H; Ohsaki, Y

GASTROENTEROLOGY 162 巻 ( 7 ) 頁： S1278 - S1279 2022年5月

The impact of the age-adjusted Charlson comorbidity index as a prognostic factor for endoscopic papillectomy in ampullary tumors. 査読有り国際誌

Journal of gastroenterology 57 巻 ( 3 ) 頁： 199 - 207 2022年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Gastroenterology

Background: The prognostic nutritional index (PNI) and Charlson comorbidity index (CCI) have been useful for predicting the prognosis based on nutritional condition and comorbidities in surgery and endoscopic mucosal dissection. The age-adjusted CCI (ACCI) has also been reported to be useful in surgery, but it has not been applied to endoscopic treatment. We therefore clarified the prognostic factors associated with ampullary tumors treated with endoscopic papillectomy (EP). Methods: From January 2003 to December 2020, 236 patients who underwent EP for sporadic ampullary tumors at Nagoya University Hospital were included in this study. The 5-year survival and ability to predict the prognosis were evaluated in terms of the sex, PNI, ACCI, final pathological diagnosis, and intraductal extension. Results: During a median follow-up period of 1558 days, 17 patients died. No patient died of the primary disease. The 5-year survival rate was 91.1%. In a univariate analysis, only a high ACCI (≥ 5) was extracted as a significant prognostic factor (Odds ratio, 12.2; 95% confidence interval, 3.81–39.3; p < 0.001). The 5-year survival rates for a low ACCI (≤ 4) and high ACCI were 96.6% and 73.5%, respectively (p < 0.001). Conclusions: A high ACCI is an important prognostic factor associated with the 5-year survival and a risk of death from other illness. Ampullary tumors suitable for EP are less likely to be a prognostic factor, and treatment-free follow-up may be acceptable in patients with a high ACCI.

DOI： 10.1007/s00535-022-01853-z

Scopus

PubMed

Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities 査読有り国際誌

Suzuki K., Igata H., Honda T., Kawashima H., Ishigami M., Abe M., Yamamoto Y.

Cancer Science 2022年2月

Preliminary Comparison of Endoscopic Brush and Net Catheters as the Sampling Tool to Analyze the Intestinal Mucus in the Rectum with Ulcerative Colitis Patients. 査読有り国際誌

Digestion 頁： 1 - 12 2022年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Digestion

Background: The pathophysiology of ulcerative colitis (UC) remains unclear, but early lesions on the colorectal mucosal surface may play an important role in its etiology. Intestinal mucus samples, including inner and outer layers, are collected by net or brush catheters, but the quality of the samples obtained by each method has not been fully investigated. Objective: The purpose of this study was to compare the microbiome and protein content of intestinal mucus collected by net and brush catheters during colonoscopy. Methods: Intestinal mucus samples from the lower rectum of 4 patients with UC were collected using a net catheter, a brush catheter, and intestinal fluid suction. Microbiome and protein content were analyzed using 16S rRNA gene sequencing and mass spectrometry. Results: The patients demonstrated significant differences in microbiome alpha diversity (p < 0.05), but this difference was not observed between the sampling methods. Net catheter samples demonstrated higher total protein concentrations than brush catheter samples. The brush catheter group had more Lachnospira, a butyrate-producing bacterium, when compared to the net group. The brush catheter group also had more oral bacteria of Staphylococcus and Dialister in those with active phase when compared to the net group. Conclusions: Brush catheters are more likely to collect the intestinal mucus inner layer, whereas net catheters are more likely to collect larger samples that include the outer mucus layer, as well as the intestinal fluid. Two sampling methods with different types of collection of the mucosa may lead to different results among patients with mucosal vulnerabilities.

DOI： 10.1159/000521929

Scopus

PubMed

Immunoproliferative Small Intestinal Disease Diagnosed by Double-balloon Endoscopy with Biopsy Sampling. 査読有り国際誌

Meza MRR, Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M

Internal medicine (Tokyo, Japan) advpub 巻 ( 0 ) 2022年2月

Factors related to delayed adverse events of endoscopic submucosal dissection in the duodenum. 査読有り国際誌

Digestive diseases (Basel, Switzerland) 2022年2月

Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreatic cancer. 査読有り国際誌

Surgical endoscopy 2022年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Surgical Endoscopy

Background: The overall survival (OS) of pancreatic cancer (PC) has been prolonged by advances in chemotherapy, and the number of cases of recurrent biliary obstruction (RBO) after self-expandable metal stent (SEMS) placement is expected to increase. We herein compared outcomes between secondary fully covered SEMS (FC) and uncovered SEMS (UC) for RBO of PC with FC placed as the 1st SEMS. Methods: Between May 2010 and March 2021, 62 PC patients who underwent SEMS exchange to FC (n = 34) or UC (n = 28) for RBO were retrospectively analyzed. Patient characteristics, OS, time to RBO (TRBO), and stent-related adverse events were compared between the FC and UC groups. Cox’s proportional hazard model was used to identify risk factors for RBO with the 2nd SEMS. Results: There was a significant difference between the FC and UC groups only in the 2nd SEMS diameter. Median OS and TRBO were 195 and 238 days in FC patients and 306 and 455 days in UC patients, respectively, with no significant differences between the two groups. No significant differences were observed in the stent-related adverse event rate. In multivariate analyses, only the 2nd SEMS diameter was significant (P = 0.009). Median TRBO were 455, 238, and 103 days in 10-mm UC, 10-mm FC, and 8-mm UC patients, with 10-mm UC patients having significantly longer TRBO than 10-mm FC and 8-mm UC patients (P = 0.020 and 0.001). Conclusion: SEMS exchange to 10-mm UC may be appropriate for RBO of PC with FC as the 1st SEMS.

DOI： 10.1007/s00464-021-08981-2

Scopus

PubMed

Differentiation Between Solid Pseudopapillary Neoplasm of the Pancreas and Nonfunctional Pancreatic Neuroendocrine Neoplasm Using Endoscopic Ultrasound. 査読有り国際誌

Pancreas 51 巻 ( 1 ) 頁： 106 - 111 2022年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Pancreas

Objectives We investigated the utility of endoscopic ultrasound (EUS) for differentiating between solid pseudopapillary neoplasm of the pancreas (SPN) and pancreatic neuroendocrine neoplasm (PanNEN). Methods A retrospective analysis was performed on 29 and 77 consecutive patients with pathologically proven SPN and nonfunctional PanNEN. In patients who underwent contrast-enhanced harmonic EUS (CH-EUS), lesions were classified into 3 vascular patterns (hypoechoic/isoechoic/hyperechoic), and the presence of "the alveolus nest sign,"which we previously reported as a characteristic feature of SPN on CH-EUS, was also assessed. Results Conventional EUS findings showed that calcification echoes were significantly more frequent in SPN lesions than in PanNEN lesions (19/29 [66%] vs 21/77 [27%], P = 0.001) as was internal isoechogenicity or hyperechogenicity (10/29 [34%] vs 11/77 [14%], P = 0.029). Contrast-enhanced harmonic EUS findings showed that SPN lesions more frequently had the isoechoic or hypoechoic vascular pattern, and significantly more frequently had the alveolus nest sign (18/25 [72%] vs 4/60 [7%], P < 0.001). In a multivariate analysis, the presence of the alveolus nest sign contributed the most to the SPN diagnosis (odds ratio, 70; 95% confidence interval, 6.2-786). Conclusions Endoscopic ultrasound, particularly the presence of the alveolus nest sign on CH-EUS, is useful for differentiating SPN from PanNEN.

DOI： 10.1097/MPA.0000000000001966

Scopus

PubMed

The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia HCC after HCV eradication in hemophilia 査読有り国際誌

Inukai Yosuke, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

ANNALS OF HEPATOLOGY 27 巻 ( 1 ) 頁： 100545 2022年

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis 査読有り国際誌

Nagoya Journal of Medical Science 84 巻 ( 1 ) 頁： 169 - 179 2022年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：Nagoya Journal of Medical Science

Ulcerative colitis (UC) is an incurable, chronic inflammatory disease of the large bowel whose etiology and pathogenesis have not yet been comprehensively explained. Tofacitinib is a small molecule Janus kinase inhibitor that was introduced for treating refractory UC. We aimed to examine the efficacy and safety of tofacitinib for the treatment of 18 patients with UC. Continuous treatment rates were 50, 38, and 33% at 8, 24, and 52 weeks, respectively. Overall, 83.3% of these patients showed tumor necrosis factor (TNF) antibody failure status. When the effective status was defined as a Lichtiger index (LI) that decreased by 3 points or more or was less than 4 points and remission status was defined as an LI less than 4 points, the effective and remission rates (%) at 2, 8, and 16 weeks were 55.5 (10/18) and 22.2 (4/18), 38.8 (7/18) and 33.3 (6/18), and 38.8 (7/18) and 38.8 (7/18), respectively. Background characteristics of 2-week responders and non-responders were compared. C-reactive protein level in responders was significantly lower than that in non-responders, and the hemoglobin level in responders was significantly higher than that in non-responders. This study provides preliminary results of the effectiveness of tofacitinib even for TNF antibody and tacrolimus failure patients.

DOI： 10.18999/nagjms.84.1.169

Scopus

Obesity and myosteatosis: the two characteristics of dynapenia in patients with cirrhosis. 査読有り国際誌

European journal of gastroenterology & hepatology 33 巻 ( 1S Suppl 1 ) 頁： e916 - e921 2021年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：European journal of gastroenterology & hepatology

OBJECTIVE: In patients with liver cirrhosis, the clinical characteristics of dynapenia, a condition in which skeletal muscle mass is maintained but muscle strength is reduced, are not yet known. This study aimed to clarify the characteristics of dynapenia and its impact on quality of life (QOL) in patients with liver cirrhosis. METHODS: We retrospectively analyzed 116 patients with cirrhosis. Based on grip strength and skeletal muscle mass measured by the bioelectrical impedance analysis method, patients were divided into four groups: normal muscle status, dynapenia, pre-sarcopenia (a condition involving only low muscle mass), and sarcopenia. The characteristics of dynapenia and its influence on QOL were examined. RESULTS: Fourteen patients had dynapenia. Liver function did not differ among the four groups. In patients with dynapenia, BMI was highest and computed tomography attenuation of skeletal muscle at the third lumbar spine vertebra was lowest among the four groups. The percentage of patients with both BMI ≥25 kg/m2 and myosteatosis was significantly higher in patients with dynapenia [9/14 (64.3%)] than in those with sarcopenia [2/23 (8.7%), P = 0.004] and pre-sarcopenia [0/18 (0%), P < 0.001] and tended to be higher than those with normal muscle status [16/61 (26.2%), P = 0.065]. The physical QOL in patients with dynapenia was as low as that in those with sarcopenia and significantly lower than that in those with normal muscle status. CONCLUSION: Cirrhotic patients with dynapenia had high BMI and myosteatosis, and impaired physical QOL.

DOI： 10.1097/MEG.0000000000002303

Scopus

PubMed

Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M

Cancer investigation 頁： 1 - 10 2021年11月

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival 査読有り国際誌

Yamada K., Nakamura M., Yamamura T., Ishikawa E., Iida T., Mizutani Y., Kakushima N., Ishikawa T., Furukawa K., Ohno E., Honda T., Ishigami M., Sawada T., Maeda K., Kawashima H., Furune S., Maeda O., Ando Y., Hase T., Hashimoto N., Yokota K., Akiyama M., Fujishiro M.

World Journal of Gastroenterology 27 巻 ( 41 ) 頁： 7190 - 7206 2021年11月

Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes. 査読有り国際誌

Imai N, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M

Anticancer research 41 巻 ( 11 ) 頁： 5817 - 5820 2021年11月

Absence of large portal collateral vessels is concerned with spontaneous improvement of cirrhotic portal vein thrombosis. 査読有り国際誌

Yokoyama S, Ishizu Y, Honda T, Imai N, Ito T, Yamamoto K, Tomoyuki T, Ishigami M

Hepatology research : the official journal of the Japan Society of Hepatology 2021年10月

Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis 査読有り国際誌

Ryuge Akihiro, Kosugi Tomoki, Maeda Kayaho, Banno Ryoichi, Gou Yang, Zaitsu Kei, Ito Takanori, Sato Yuka, Hirayama Akiyoshi, Tsubota Shoma, Honda Takashi, Nakajima Kazuki, Ozaki Tomoya, Kondoh Kunio, Takahashi Kazuo, Kato Noritoshi, Ishimoto Takuji, Soga Tomoyoshi, Nakagawa Takahiko, Koike Teruhiko, Arima Hiroshi, Yuzawa Yukio, Minokoshi Yasuhiko, Maruyama Shoichi, Kadomatsu Kenji

JCI INSIGHT 6 巻 ( 20 ) 2021年10月

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies 査読有り国際誌

Ito Takanori, Ishigami Masatoshi, Yamamoto Takafumi, Mizuno Kazuyuki, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Kawashima Hiroki, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Kato Masashi, Hashimoto Naozumi, Hibi Hideharu, Kodera Yasuhiro, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Shimoyama Yoshie, Fujishiro Mitsuhiro

HEPATOLOGY INTERNATIONAL 15 巻 ( 5 ) 頁： 1278 - 1287 2021年10月

Factors associated with bleeding after endoscopic variceal ligation in children 査読有り国際誌

Yokoyama Shinya, Ishizu Yoji, Ishigami Masatoshi, Honda Takashi, Kuzuya Teiji, Ito Takanori, Hinoki Akinari, Sumida Wataru, Shirota Chiyoe, Tainaka Takahisa, Makita Satoshi, Yokota Kazuki, Uchida Hiroo, Fujishiro Mitsuhiro

PEDIATRICS INTERNATIONAL 63 巻 ( 10 ) 頁： 1223 - 1229 2021年10月

Differentiation between pancreatic metastases from renal cell carcinoma and pancreatic neuroendocrine neoplasm using endoscopic ultrasound. 査読有り国際誌

Kataoka K, Ishikawa T, Ohno E, Mizutani Y, Iida T, Ishikawa E, Furukawa K, Nakamura M, Honda T, Ishigami M, Kawashima H, Hirooka Y, Fujishiro M

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 21 巻 ( 7 ) 頁： 1364 - 1370 2021年10月

Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis 査読有り国際誌

Muto Hisanori, Ito Takanori, Tanaka Taku, Yokoyama Shinya, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Maeda Keiko, Honda Takashi, Ishikawa Tetsuya, Kato Asuka, Ohshiro Taichi, Kano Fumiya, Yamamoto Akihito, Sakai Kiyoshi, Hibi Hideharu, Ishigami Masatoshi, Fujishiro Mitsuhiro

SCIENTIFIC REPORTS 11 巻 ( 1 ) 頁： 18778 2021年9月

Revisiting Prognosis After Liver Transplant in Patients Positive for Hepatitis C Virus: Focus on Hepatitis C Recurrence-Unrelated Complications 査読有り国際誌

Ishigami Masatoshi, Honda Takashi, Ishizu Yoji, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Kamei Hideya, Ogura Yasuhiro, Fujishiro Mitsuhiro

EXPERIMENTAL AND CLINICAL TRANSPLANTATION 19 巻 ( 9 ) 頁： 935 - 942 2021年9月

Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation A STROBE-compliant retrospective observational study 査読有り国際誌

Muto Hisanori, Kuzuya Teiji, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishikawa Tetsuya, Ishigami Masatoshi, Fujishiro Mitsuhiro

MEDICINE 100 巻 ( 31 ) 頁： e26820 2021年8月

Feasibility of patency capsule and colon capsule endoscopy in patients with suspected gastrointestinal stenosis: a prospective study 査読有り国際誌

Otsuka Hiroyuki, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawade Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Iliroki, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

NAGOYA JOURNAL OF MEDICAL SCIENCE 83 巻 ( 3 ) 頁： 419 - 430 2021年8月

Fecal incontinence and oral regurgitation during duodenal endoscopic submucosal dissection using the water pressure method 査読有り国際誌

Takada Yoshihisa, Hirose Takashi, Nishida Kazuki, Kakushima Naomi, Furukawa Kazuhiro, Furune Satoshi, Ishikawa Eri, Sawada Tsunaki, Maeda Keiko, Yamamura Takeshi, Ishikawa Takuya, Ohno Eizaburo, Nakamura Masanao, Honda Takashi, Ishigami Masatoshi, Kawashima Hiroki, Fujishiro Mitsuhiro

DIGESTIVE ENDOSCOPY 2021年7月

Endoscopic papillectomy for ampullary adenoma and early adenocarcinoma: Analysis of factors related to treatment outcome and long-term prognosis. 査読有り国際誌

Kawashima H, Ohno E, Ishikawa T, Iida T, Tanaka H, Furukawa K, Nakamura M, Honda T, Hashimoto S, Itoh A, Ishigami M, Hirooka Y, Fujishiro M

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 巻 ( 5 ) 頁： 858 - 869 2021年7月

Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn's disease. 査読有り国際誌

Nishikawa T, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

Journal of gastroenterology and hepatology 36 巻 ( 7 ) 頁： 1851 - 1858 2021年7月

An initial trial of quantitative evaluation of autoimmune pancreatitis using shear wave elastography and shear wave dispersion in transabdominal ultrasound. 査読有り国際誌

Suzuki H, Ishikawa T, Ohno E, Iida T, Uetsuki K, Yashika J, Yamada K, Yoshikawa M, Furukawa K, Nakamura M, Honda T, Ishigami M, Kawashima H, Fujishiro M

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 21 巻 ( 4 ) 頁： 682 - 687 2021年6月

Immunohistochemical staining for IMP3 in patients with duodenal papilla tumors: assessment of the potential for diagnosing endoscopic resectability and predicting prognosis 査読有り国際誌

Tanaka Hiroyuki, Kawashima Hiroki, Ohno Eizaburo, Ishikawa Takuya, Iida Tadashi, Ishikawa Eri, Furukawa Kazuhiro, Nakamura Masanao, Honda Takashi, Shimoyama Yoshie, Miyahara Ryoji, Kawabe Naoto, Kuzuya Teiji, Hashimoto Senju, Ishigami Masatoshi, Hirooka Yoshiki, Fujishiro Mitsuhiro

BMC GASTROENTEROLOGY 21 巻 ( 1 ) 頁： 224 2021年5月

Measurement of fasting breath hydrogen concentration as a simple diagnostic method for pancreatic exocrine insufficiency 査読有り国際誌

Uetsuki Kota, Kawashima Hiroki, Ohno Eizaburo, Ishikawa Takuya, Iida Tadashi, Yamamoto Kenta, Furukawa Kazuhiro, Nakamura Masanao, Honda Takashi, Ishigami Masatoshi, Hirooka Yoshiki, Fujishiro Mitsuhiro

BMC GASTROENTEROLOGY 21 巻 ( 1 ) 頁： 211 2021年5月

Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs 査読有り国際誌

Yamamoto Takafumi, Imai Norihiro, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Honda Takashi, Okamoto Shuichi, Kanematsu Takeshi, Suzuki Nobuaki, Matsushita Tadashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

ANTICANCER RESEARCH 41 巻 ( 5 ) 頁： 2569 - 2573 2021年5月

Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer 査読有り国際誌

Yoshikawa Masakatsu, Ishikawa Takuya, Ohno Eizaburo, Iida Tadashi, Furukawa Kazuhiro, Nakamura Masanao, Honda Takashi, Ishigami Masatoshi, Kinoshita Fumie, Kawashima Hiroki, Fujishiro Mitsuhiro

SCIENTIFIC REPORTS 11 巻 ( 1 ) 頁： 7409 2021年4月

Filtrated Adipose Tissue-Derived Mesenchymal Stem Cell Lysate Ameliorates Experimental Acute Colitis in Mice. 査読有り国際誌

Nishikawa T, Maeda K, Nakamura M, Yamamura T, Sawada T, Mizutani Y, Ito T, Ishikawa T, Furukawa K, Ohno E, Miyahara R, Kawashima H, Honda T, Ishigami M, Yamamoto T, Matsumoto S, Hotta Y, Fujishiro M

Digestive diseases and sciences 66 巻 ( 4 ) 頁： 1034 - 1044 2021年4月

Impact of visceral fat accumulation on the prognosis of patients with cirrhosis 査読有り国際誌

Ishizu Yoji, Ishigami Masatoshi, Honda Takashi, Imai Norihiro, Ito Takanori, Yamamoto Kenta, Fujishiro Mitsuhiro

CLINICAL NUTRITION ESPEN 42 巻頁： 354 - 360 2021年4月

Quality of Life in patients with nonalcoholic fatty liver disease: Structure and related factors focusing on illness uncertainty 査読有り国際誌

Ozawa Naoki, Sato Kazuki, Sugimura Ayumi, Maki Shigeyoshi, Tanaka Taku, Yamamoto Kenta, Ito Takanori, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro, Ishikawa Tetsuya, Ando Shoko

JAPAN JOURNAL OF NURSING SCIENCE 18 巻 ( 3 ) 頁： e12415 2021年3月

Simplification of balloon-occluded retrograde transcatheter obliteration procedure using a coaxial double balloon catheter compared with a single-balloon catheter. 査読有り国際誌

Ishizu Y, Ishigami M, Honda T, Kuzuya T, Ito T, Komada T, Fujishiro M

Japanese journal of radiology 39 巻 ( 3 ) 頁： 296 - 302 2021年3月

Progression After Molecular Targeted Agents: Hepatic Arterial Changes and Transarterial Chemoembolization in Hepatocellular Carcinoma. 査読有り国際誌

Matsuda N, Imai N, Kuzuya T, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Fujishiro M

In vivo (Athens, Greece) 35 巻 ( 2 ) 頁： 1185 - 1189 2021年3月

Endoscopic ultrasound elastography for small solid pancreatic lesions with or without main pancreatic duct dilatation. 査読有り国際誌

Kataoka K, Ishikawa T, Ohno E, Iida T, Suzuki H, Uetsuki K, Furukawa K, Nakamura M, Honda T, Ishigami M, Kawashima H, Hirooka Y, Fujishiro M

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 21 巻 ( 2 ) 頁： 451 - 458 2021年3月

Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. 査読有り国際誌

Yashika J, Ohno E, Ishikawa T, Iida T, Suzuki H, Uetsuki K, Yamada K, Yoshikawa M, Gibo N, Shimoyama Y, Ishikawa E, Furukawa K, Nakamura M, Honda T, Ishigami M, Hirooka Y, Kawashima H, Fujishiro M

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 21 巻 ( 2 ) 頁： 390 - 396 2021年3月

Diagnostic yield of colon capsule endoscopy for Crohn's disease lesions in the whole gastrointestinal tract 査読有り国際誌

Yamada Keisaku, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

BMC GASTROENTEROLOGY 21 巻 ( 1 ) 頁： 75 2021年2月

進行肝細胞癌に対するレンバチニブPD後のラムシルマブ治療の初期経験査読有り国際誌

葛谷貞二, 石上雅敏, 杉山由晃, 吉岡直輝, 水野和幸, 武藤久哲, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 本多隆, 石川哲也, 藤城光弘

Pharma Medica 39 巻 ( 2 ) 頁： 72 - 73 2021年2月

Ustekinumab is effective against small bowel lesions in Crohn's disease: two case reports. 査読有り国際誌

Murate K, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Kakushima N, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

Clinical journal of gastroenterology 14 巻 ( 1 ) 頁： 129 - 135 2021年2月

Systematic review and meta-analysis of the diagnostic and therapeutic yield of small bowel endoscopy in patients with overt small bowel bleeding. 査読有り国際誌

Uchida G, Nakamura M, Yamamura T, Furukawa K, Kawashima H, Honda T, Ishigami M, Fujishiro M

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 巻 ( 1 ) 頁： 66 - 82 2021年1月

Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia 査読有り国際誌

HAEMOPHILIA 27 巻 ( 1 ) 頁： 100 - 107 2021年1月

Clinical Features of Ischemic Enteritis Diagnosed by Double-Balloon Endoscopy. 査読有り国際誌

Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Kakushima N, Furukawa K, Ishikawa T, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

Canadian journal of gastroenterology & hepatology 2021 巻頁： 8875564 2021年

Increased Frequency of Dysfunctional Siglec-7-CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. 査読有り国際誌

Sakamoto Y, Yoshio S, Doi H, Mori T, Matsuda M, Kawai H, Shimagaki T, Yoshikawa S, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Atsukawa M, Ito T, Honda T, Mise Y, Ono Y, Takahashi Y, Saiura A, Taketomi A, Kanto T

Frontiers in immunology 12 巻頁： 603133 2021年

顕性小腸出血患者における小腸内視鏡の診断能と治療能に関するシステマティックレビューとメタ解析査読有り

内田元太, 中村正直, 山村健史, 古川和宏, 川嶋啓揮, 本多隆, 石上雅敏, 藤城光弘

日本消化器内視鏡学会雑誌 63 巻 ( 9 ) 頁： 1649 - 1665 2021年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人日本消化器内視鏡学会

【背景】小腸カプセル内視鏡（SBCE）やバルーン内視鏡（BAE）といった小腸内視鏡は小腸出血（SBB）の診療において有用である．しかしながら，特に顕性小腸出血（overt SBB）に対するマネジメント方法は未だ確立されていない．本メタ解析は，overt SBB診療における小腸内視鏡の統合された診断能（DYs）と統合された治療能（TYs）を評価し，内視鏡の適切なタイミングを決定することを目的とした．【方法】Overt SBBにおける小腸内視鏡のDYまたはTYを評価した研究を検索した．DY，TY，内視鏡のタイミングに関するデータが抽出され，統合そして解析された．Overt SBB患者における小腸内視鏡の統合されたDYと統合されたTYが算出された．さらにメタ回帰分析とサブグループ解析が行われた．【結果】22個の研究が選択された．統合されたDYはSBCEとBAEでそれぞれ65.2％，74.0％であった．統合されたTYはSBCEとBAEでそれぞれ55.9％，35.8％であった．メタ回帰分析では，内視鏡のタイミングがBAEのDY，さらにSBCEとBAEのTYと有意に関連していた．【結論】SBCEとBAEはovert SBB診療において有用な診断と治療のモダリティと思われた．サブグループ解析ではSBCEとBAEのTYは出血後２日以内でより高い傾向にあり，適切な内視鏡のタイミングは出血後２日以内と考えられた．

DOI： 10.11280/gee.63.1649

Scopus

自己免疫性膵炎の活動性評価を目的とした超音波内視鏡下shear-wave測定の臨床的実現可能性と有用性の検討：前向き探索的研究査読有り

大野栄三郎, 本多隆, 廣岡芳樹, 川嶋啓揮, 石川卓哉, 田中浩敬, 酒井大輔, 石津洋二, 葛谷貞二, 中村正直

超音波医学 48 巻 ( 1 ) 頁： 35 - 44 2021年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：公益社団法人日本超音波医学会

目的：自己免疫性膵炎（AIP）の診断および治療における，新開発された超音波内視鏡検査（EUS）のshear-wave（せん断波）elastography法（EUS shear-wave測定：EUS-SWM）の臨床的実現可能性と有用性を評価する．方法：患者160名の膵臓の組織弾性を測定した．EUS-SWMの成功率，shear-wave速度（Vs, m/s），およびVs測定の信頼度指数（VsN）を評価し，弾性（平均Vs）をAIP群（n＝14）および正常対照群との間で比較した．結果：有害事象はなく合計3,837件のEUS-SWMを実施した．全体の測定成功率は97.6％（3,743/3,837）であった．平均VsNは74％であった．膵臓の平均Vsは，次のとおりであった．膵頭部（十二指腸球部より観察：プッシュポジション）では2.22 m/s，膵頭部（十二指腸下行脚より観察：プルポジション）では2.36 m/s，膵体部では1.99 m/s，そして膵尾部では2.25 m/s．AIP群（2.57 m/s）の平均Vsは，正常対照群の平均Vs（1.89 m/s）（P＝0.0185）に比べて有意に高かった．平均Vsは，ステロイド治療（n＝6）（P＝0.0234）後，3.32 m/sから2.46 m/sへと有意に減少した．結論：EUS-SWMは臨床的に実現可能な手技であり，信頼性のある結果が得られた．EUS-SWMは，AIP患者へのステロイド治療の効果を評価する上で有効な方法である．

DOI： 10.3179/jjmu.JJMU.K.22

*The microbiome can predict mucosal healing in small intestine in patients with Crohn's disease. 査読有り国際誌

Hattori S, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Yamamoto K, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Hirooka Y, Fujishiro M

55 巻 ( 12 ) 頁： 1138 - 1149 2020年12月

Accuracy of carbon dioxide insufflation for endoscopic retrograde cholangiopancreatography using double-balloon endoscopy 査読有り国際誌

Niwa Yoshiki, Nakamura Masanao, Kawashima Hiroki, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

WORLD JOURNAL OF GASTROENTEROLOGY 26 巻 ( 42 ) 頁： 6669 - 6678 2020年11月

Endoscopic Activity and Serum TNF-alpha Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients 査読有り国際誌

Murate Kentaro, Maeda Keiko, Nakamura Masanao, Sugiyama Daisuke, Wada Hirotaka, Yamamura Takeshi, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Miyahara Ryoji, Ishigami Masatoshi, Nishikawa Hiroyoshi, Fujishiro Mitsuhiro

INFLAMMATORY BOWEL DISEASES 26 巻 ( 11 ) 頁： 1669 - 1681 2020年11月

The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC 査読有り国際誌

Ito Takanori, Ishigami Masatoshi, Morooka Hikaru, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Nishimura Daisaku, Tada Toshifumi, Yasuda Satoshi, Toyoda Hidenori, Kumada Takashi, Fujishiro Mitsuhiro

SCIENTIFIC REPORTS 10 巻 ( 1 ) 頁： 17812 2020年10月

Revisiting the indications for liver transplantation in cirrhotic patients considering the long-term outcomes of cirrhotic patients. 査読有り国際誌

Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Ogura Y, Fujishiro M

Journal of hepato-biliary-pancreatic sciences 27 巻 ( 9 ) 頁： 655 - 662 2020年9月

Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. 査読有り国際誌

Nomura A, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Onishi Y, Ogura Y, Fujishiro M

Medicine 99 巻 ( 28 ) 頁： e21161 2020年7月

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies 査読有り国際誌

Mizuno Kazuyuki, Ito Takanori, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Kawashima Hiroki, Inukai Yosuke, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Maeda Osamu, Kiyoi Hitoshi, Nagino Masato, Hibi Hideharu, Kodera Yasuhiro, Fujimoto Yasushi, Sone Michihiko, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Fujishiro Mitsuhiro

JOURNAL OF GASTROENTEROLOGY 55 巻 ( 6 ) 頁： 653 - 661 2020年6月

Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease 査読有り国際誌

Ito Takanori, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Ishikawa Tetsuya, Toyoda Hidenori, Kumada Takashi, Fujishiro Mitsuhiro

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 32 巻 ( 6 ) 頁： 748 - 753 2020年6月

Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report. 査読有り国際誌

Muto H, Kuzuya T, Ito T, Ishizu Y, Honda T, Ishikawa T, Ishigami M, Fujishiro M

Clinical journal of gastroenterology 13 巻 ( 3 ) 頁： 397 - 402 2020年6月

Nonexposed wall-inversion surgery as a novel local resection method for neoplasms in the gastrointestinal tract. 査読有り国際誌

Fujishiro M, Furukawa K, Yamamura T, Nakamura M, Honda T, Maeda O, Ishigami M, Kawashima H

Nagoya journal of medical science 82 巻 ( 2 ) 頁： 175 - 182 2020年5月

Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. 査読有り国際誌

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M

Anticancer research 40 巻 ( 4 ) 頁： 2283 - 2290 2020年4月

Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. 査読有り国際誌

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M

Anticancer research 40 巻 ( 4 ) 頁： 2089 - 2093 2020年4月

Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma 査読有り国際誌

Kuzuya Teiji, Ishigami Masatoshi, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishikawa Tetsuya, Fujishiro Mitsuhiro

HEPATOLOGY RESEARCH 50 巻 ( 3 ) 頁： 374 - 381 2020年3月

*Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon. 査読有り国際共著国際誌

Zorron Cheng Tao Pu L, Yamamoto K, Honda T, Nakamura M, Yamamura T, Hattori S, Burt AD, Singh R, Hirooka Y, Fujishiro M

Journal of gastroenterology and hepatology 35 巻 ( 3 ) 頁： 433 - 437 2020年3月

Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib. 査読有り国際誌

Yamamoto K, Kuzuya T, Honda T*, Ito T, Ishizu Y, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Fujishiro M

Anticancer research 40 巻 ( 2 ) 頁： 665 - 676 2020年2月

Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. 査読有り国際誌

Yoshioka N, Ishigami M, Watanabe Y, Sumi H, Doisaki M, Yamaguchi T, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Haruta JI, Fujishiro M

Scientific reports 10 巻 ( 1 ) 頁： 481 2020年1月

Development of a novel anti-hepatitis B virus agent via Sp1 査読有り国際誌

Hayakawa Michiyo, Umeyama Hideaki, Iwadate Mitsuo, Taguchi Y. -H., Yano Yoshihiko, Honda Takashi, Itami-Matsumoto Saori, Kozuka Ritsuzo, Enomoto Masaru, Tamori Akihiro, Kawada Norifumi, Murakami Yoshiki

SCIENTIFIC REPORTS 10 巻 ( 1 ) 頁： 47 2020年1月

Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection 査読有り国際誌

Ishizu Yoji, Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Kuzuya Teiji, Ito Takanori, Fujishiro Mitsuhiro

HEPATOLOGY RESEARCH 50 巻 ( 1 ) 頁： 47 - 56 2020年1月

Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. 査読有り国際誌

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M

Nutrition and cancer 72 巻 ( 5 ) 頁： 884 - 891 2020年

Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. 査読有り国際誌

Tanaka T, Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M

Oncology 98 巻 ( 9 ) 頁： 621 - 629 2020年

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis 査読有り国際誌

Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ohashi Ayako, Kajikawa Go, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Ishigami Masatoshi, Fujishiro Mitsuhiro

INTERNAL MEDICINE 59 巻 ( 23 ) 頁： 3009 - 3014 2020年

A Prospective Study of Factors Associated with Abdominal Pain in Patients during Unsedated Colonoscopy Using a Magnifying Endoscope. 査読有り国際誌

Suzuki H, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M

Internal medicine (Tokyo, Japan) 59 巻 ( 15 ) 頁： 1795 - 1801 2020年

Sarcopenia impairs health-related quality of life in cirrhotic patients. 査読有り国際誌

Ando Y, Ishigami M, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Fujishiro M

European journal of gastroenterology & hepatology 31 巻 ( 12 ) 頁： 1550 - 1556 2019年12月

Spleen stiffness by 2-D shear wave elastography is the most accurate predictor of high-risk esophagogastric varices in children with biliary atresia 査読有り国際誌

Yokoyama Shinya, Ishigami Masatoshi, Honda Takashi, Kuzuya Teiji, Ishizu Yoji, Ito Takanori, Hirooka Yoshiki, Tanaka Yujiro, Tainaka Takahisa, Shirota Chiyoe, Chiba Kosuke, Uchida Hiroo, Fujishiro Mitsuhiro

HEPATOLOGY RESEARCH 49 巻 ( 10 ) 頁： 1162 - 1168 2019年10月

Feasibility and usefulness of endoscopic ultrasonography-guided shear-wave measurement for assessment of autoimmune pancreatitis activity: a prospective exploratory study. 査読有り国際誌

Ohno E, Hirooka Y, Kawashima H, Ishikawa T, Tanaka H, Sakai D, Ishizu Y, Kuzuya T, Nakamura M, Honda T

Journal of medical ultrasonics (2001) 46 巻 ( 4 ) 頁： 425 - 433 2019年10月

Antifibrotic Effects of 1,25(OH)2D3 on Nonalcoholic Steatohepatitis in Female Mice. 査読有り国際誌

Ma L, Ishigami M, Honda T, Yokoyama S, Yamamoto K, Ishizu Y, Kuzuya T, Hayashi K, Hirooka Y, Goto H.

Digestive diseases and sciences 64 巻 ( 9 ) 頁： 2581 - 2590 2019年9月

Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. 査読有り国際誌

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Hirooka Y, Fujishiro M

Hepatology research : the official journal of the Japan Society of Hepatology 49 巻 ( 9 ) 頁： 1054 - 1065 2019年9月

Complete response by vitamin K2 analog monotherapy in sorafenib-failure advanced hepatocellular carcinoma: A case report. 査読有り国際誌

Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Ishikawa T, Hirooka Y, Goto H.

Hepatol Res. 49 巻 ( 3 ) 頁： 360-364 2019年3月

Successful treatment of esophageal bleeding due to rupture of major aortopulmonary collateral arteries by transcatheter arterial embolization. 査読有り国際誌

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Matsushima M, Kato T, Hirooka Y

Clinical journal of gastroenterology 12 巻 ( 1 ) 頁： 20 - 24 2019年2月

Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. 査読有り国際誌

Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, Toyoda H, Kumada T, Goto H, Hirooka Y

Journal of gastroenterology and hepatology 34 巻 ( 1 ) 頁： 207 - 214 2019年1月

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity 査読有り国際誌

Yoshioka Naoki, Kuzuya Teiji, Ito Takanori, Ishizu Yoji, Honda Takashi, Ishikawa Tetsuya, Ishigami Masatoshi, Fujishiro Mitsuhiro

INTERNAL MEDICINE 58 巻 ( 19 ) 頁： 2803 - 2808 2019年

The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy. 査読有り国際誌

Hayashi K, Tachi K, Shimizu Y, Nagano K, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Hirooka Y, Hattori M, Goto H

Intervirology 62 巻 ( 1 ) 頁： 23 - 29 2019年

Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. 査読有り国際誌

Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, Toyoda H, Kumada T, Hattori M, Katano Y, Goto H.

J Viral Hepat. 25 巻 ( 12 ) 頁： 1446 - 1451 2018年12月

Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma. 査読有り国際誌

Ando Y, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y

Clinical journal of gastroenterology 11 巻 ( 6 ) 頁： 514 - 520 2018年12月

Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication. 査読有り国際誌

Yasuda S, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Toyoda H, Kumada T, Hirooka Y, Goto H.

J Gastroenterol Hepatol 33 巻 ( 11 ) 頁： 1904-1911 2018年11月

Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease. 査読有り国際誌

Tachi Y, Kozuka A, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

Nutrition 54 巻頁： 83-88 2018年10月

Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. 査読有り国際誌

Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H, Katano Y.

Eur J Gastroenterol Hepatol. 30 巻 ( 9 ) 頁： 1066-1072 2018年9月

Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93 査読有り国際誌

Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Kuzuya Teiji, Ishizu Yoji, Ishikawa Tetsuya, Nakano Isao, Urano Fumihiro, Kumada Takashi, Yoshioka Kentaro, Hirooka Yoshiki, Goto Hidemi

JOURNAL OF MEDICAL VIROLOGY 90 巻 ( 4 ) 頁： 736 - 744 2018年4月

Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease. 査読有り国際誌

Tachi Y, Kozuka A, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

J Gastroenterol Hepatol 2018年2月

Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy 査読有り国際誌

Hayashi Kazuhiko, Ishigami Masatoshi, Yasuda Satoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Ishikawa Tetsuya, Hirooka Yoshiki, Goto Hidemi

HEPATOLOGY RESEARCH 48 巻 ( 3 ) 頁： E78 - E86 2018年2月

Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. 査読有り国際誌

Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Ishikawa T, Nakano I, Hirooka Y, Goto H

Oncology 95 巻 ( 2 ) 頁： 91 - 99 2018年

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals. 査読有り国際誌

Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H

JGH open : an open access journal of gastroenterology and hepatology 1 巻 ( 1 ) 頁： 44 - 49 2017年9月

Utility of Doppler ultrasonography for diagnosing and assessing treatment effects in liver compartment syndrome 査読有り国際誌

Ando Yusuke, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishikawa Tetsuya, Goto Hidemi, Hirooka Yoshiki

CLINICAL JOURNAL OF GASTROENTEROLOGY 10 巻 ( 3 ) 頁： 265 - 269 2017年6月

Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction 査読有り国際誌

Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Kuzuya Teiji, Ishizu Yoji, Ishikawa Tetsuya, Nakano Isao, Urano Fumihiro, Kumada Takashi, Yoshioka Kentaro, Goto Hidemi, Hirooka Yoshiki

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 15 巻 ( 5 ) 頁： 787 - 788 2017年5月

Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. 査読有り国際誌

Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, Kumada T.

Antivir Ther. 22 巻 ( 3 ) 頁： 185 - 193 2017年

Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data. 査読有り国際誌

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y.

J Gastroenterol Hepatol 32 巻 ( 11 ) 頁： 1879-1886 2017年

Low skeletal muscle mass predicts early mortality in cirrhotic patients with acute variceal bleeding. 査読有り国際誌

Ishizu Y, Ishigami M, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Hirooka Y, Goto H.

Nutrition. 42 巻頁： 87-91 2017年

Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. 査読有り国際誌

Ando Y, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Nakano I, Hirooka Y, Goto H.

Hepatol Res 2017年

Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. 査読有り国際誌

Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H.

Hepatol Res 2017年

Liver stiffness reduction correlates with histological characteristics of Hepatitis C patients with sustained virological response 査読有り国際誌

Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

Liver Int. 38 巻 ( 1 ) 頁： 59 - 67 2017年

A comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b 査読有り国際誌

Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Kawashima H, Ishikawa T, Tachi Y, Hattori M, Katano Y, Goto H, Hirooka Y.

J Gastroenterol Hepatol 2017年

Hepatocyte-Specific Depletion of Ubiquitin Regulatory X Domain Containing Protein 8 Accelerates Fibrosis in a Mouse Non-Alcoholic Steatohepatitis Model 査読有り国際誌

Imai N, Suzuki M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishigami M, Hirooka Y, Ishikawa T, Goto H, Fujimoto T.

Histochemistry and Cell Biology 183 巻 ( 3 ) 頁： 219-227 2017年

Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy 査読有り国際誌

Hayashi Kazuhiko, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Tachi Yoshihiko, Ishikawa Tetsuya, Katano Yoshiaki, Yoshioka Kentaro, Toyoda Hidenori, Kumada Takashi, Goto Hidemi, Hirooka Yoshiki

JOURNAL OF GASTROENTEROLOGY 51 巻 ( 11 ) 頁： 1081 - 1089 2016年11月

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. 査読有り国際誌

Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Ishikawa T, Nakano I, Goto H, Hirooka Y.

Oncology. 91 巻 ( 5 ) 頁： 261-266 2016年9月

A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? 査読有り国際誌

Hayashi Kazuhiko, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Nishimura Daisaku, Goto Hidemi, Hirooka Yoshiki

CLINICAL JOURNAL OF GASTROENTEROLOGY 9 巻 ( 4 ) 頁： 252 - 256 2016年8月

Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus-infected patients with a sustained virological response. 査読有り国際誌

Tachi Y, Hirai T, Kojima Y, Miyata A, Ohara K, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

Alimentary Pharmacology Therapeutics 44 巻 ( 4 ) 頁： 346-55 2016年6月

Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, Kumada T, Goto H, Hirooka Y.

J Gastroenterol. 51 巻 ( 11 ) 頁： 1081-1089 2016年3月

*DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. 査読有り国際誌

Achiwa K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Katano Y, Goto H.

Biochem Biophys Res Commun 470 巻 ( 1 ) 頁： 15 - 21 2016年1月

α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response 査読有り国際誌

Tachi Y, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

J Gastroenterol Hepatol 31 巻 ( 5 ) 頁： 1001 - 1008 2016年

Real world data of daclatasvir and asunaprevir combination therapy for HCV genotype 1b infection in patients with renal dysfunction 査読有り国際誌

Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y.

Clin Gastroenterol Hepatol. 15 巻 ( 5 ) 頁： 787-788 2016年

Immunoglobulin G4-associated autoimmune hepatitis later complicated by autoimmune pancreatitis: A case report. 査読有り国際誌

Ishizu Y, Ishigami M, Kuzuya T, Honda T, Hayashi K, Nakano I, Hirooka Y, Goto H.

Hepatol Res 46 巻 ( 6 ) 頁： 601-6 2015年10月

*Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. 査読有り国際誌

Luo F, Ishigami M, Achiwa K, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Katano Y, Goto H.

Dig Dis Sci 60 巻 ( 9 ) 頁： 2730-2739 2015年9月

Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. 査読有り国際誌

Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Katano Y, Hirooka Y, Ishikawa T, Nakano I, Goto H.

ProS One. 10 巻 ( 9 ) 頁： e0138776 2015年9月

Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. 査読有り国際誌

Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S

International journal of hematology 102 巻 ( 3 ) 頁： 379 - 82 2015年9月

Association between responses to interferon therapy and genetic variation in interferon -28B and the core region of hepatitis C virus gentype 3a 査読有り国際誌

Yamada K, Ishigami M, Kuzuya T, Honda T, Hayashi K, Goto H.

J Med Virol. 87 巻 ( 8 ) 頁： 1361-1367 2015年8月

Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. 査読有り国際誌

Niwa Y, Ishikawa K, Ishigami M, Honda T, Achiwa K, Izumoto T, Maekawa R, Hosokawa K, Iida A, Seino Y, Hamada Y, Goto H, Oiso Y, Arima H, Tsunekawa S.

Biochem Biophys Res Commun 463 巻 ( 3 ) 頁： 344 - 350 2015年7月

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. 査読有り国際誌

Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T.

ProS One. 10 巻 ( 7 ) 頁： e0133515 2015年7月

Evaluation of Liver Function in Patients With Liver Cirrhosis-Comparison of Child-Pugh Score and MELD Score 査読有り国際誌

Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Kuzuya Teiji, Ishizu Yoji, Onishi Yasuharu, Kamei Hideya, Ogura Yasuhiro, Goto Hidemi

99 巻頁： 170 - 170 2015年7月

*Hepatitis B e antigen and hepatitis B surface antigen seroclearance with emergence of lamivudine-associated mutation and core mutation after elevation of CD4 in a patient with hepatitis B and HIV 査読有り国際誌

Honda T, Ishigami M, Luo F, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Katano Y, Goto H.

Internal Medicine 54 巻 ( 6 ) 頁： 585-590 2015年6月

Endoscopic treatment of esophageal varices on hemophilic patients with liver cirrohosis 査読有り国際誌

Ishizu Y, Ishigami M, Kuzuya T, Honda T, Hayashi K, Goto H.

Gastrointest Endosc 81 巻 ( 4 ) 頁： 1059-1060 2015年4月

Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. 査読有り国際誌

Tachi Y, Hirai T, Miyata A, Ohara K, Iida T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H.

Hepatol Res. 45 巻 ( 2 ) 頁： 238 - 246 2015年1月

Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness 査読有り国際誌

Hayashi K, Katano Y, Ishuzu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Gastroenterol Hepatol 30 巻 ( 1 ) 頁： 178-183 2015年1月

Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. 査読有り国際誌

Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H

World journal of hepatology 6 巻 ( 12 ) 頁： 844 - 50 2014年12月

Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients 査読有り国際誌

Ishigami M, Honda T, Ishizu Y, Onishi Y, Kamei H, Hayashi K, Ogura Y, Hirooka Y, Goto H.

Liver Transpl. 20 巻 ( 10 ) 頁： 1211-1120 2014年10月

A pediatric case of hepatitis B virus subgenotype A2 in Japan. 査読有り国際誌

Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Ito Y, Kimura H, Katano Y, Goto H

Clinical journal of gastroenterology 6 巻 ( 5 ) 頁： 383 - 5 2013年10月

進行肝細胞癌に対するソラフェニブ投与後2週間以内の発熱と造影CT上の阻血性変化との関係査読有り

葛谷貞二, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 本多隆, 林和彦, 石川哲也, 中野功, 片野義明, 伊藤彰浩, 廣岡芳樹, 後藤秀実

肝臓 54 巻 ( 7 ) 頁： 505 - 506 2013年7月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人　日本肝臓学会

We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

DOI： 10.2957/kanzo.54.505

An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. 査読有り国際誌

Imai N, Katano Y, Kuzuya T, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Goto H.

Hepatogastroenterology 60 巻 ( 125 ) 頁： 965 - 970 2013年6月

Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B. 査読有り国際誌

Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

Hepatol Res 43 巻 ( 6 ) 頁： 580-588 2013年

穿刺治療支援アプリケーションVirtuTRAXTMを用いた2ステップ法によるラジオ波焼灼術の試み査読有り

葛谷貞二, 林和彦, 石上雅敏, 石川哲也, 中野功, 片野義明, 伊藤彰浩, 廣岡芳樹, 泉並木, 後藤秀実, 石津洋二, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 本多隆

肝臓 54 巻 ( 12 ) 頁： 850 - 853 2013年

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：一般社団法人　日本肝臓学会

We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAXTM (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAXTM position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAXTM is suggested to be more safe and effective than conventional RFA.

DOI： 10.2957/kanzo.54.850

Role of naofen in apoptosis of hepatocytes induced by lipopolysaccharide through mitochondrial signaling in rats 査読有り国際誌

Fan JH, Feng GG, Huang L, Tsunekawa K, Honda T, Katano Y, Hirooka Y, Goto H, Kandatsu N, Ando K, Fujiwara Y, Koide T, Okada S, Ishikawa N.

Hepatol Res 42 巻 ( 7 ) 頁： 696-705 2012年7月

Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C 査読有り国際誌

Ishizu Yoji, Katano Yoshiaki, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Nakano Isao, Goto Hidemi

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 巻 ( 6 ) 頁： 1112 - 1116 2012年6月

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin. 査読有り国際誌

Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Med Virol. 84 巻 ( 3 ) 頁： 438-444 2012年3月

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. 査読有り国際誌

Toyoda H, Kumada T, Tada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 84 巻 ( 1 ) 頁： 61-70 2012年1月

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy 査読有り国際誌

Hayashi Kazuhiko, Katano Yoshiaki, Honda Takashi, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Ishikawa Tetsuya, Nakano Isao, Yoshioka Kentaro, Toyoda Hidenori, Kumada Takashi, Goto Hidemi

LIVER INTERNATIONAL 31 巻 ( 9 ) 頁： 1359 - 1365 2011年10月

Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. 査読有り国際誌

Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 83 巻 ( 9 ) 頁： 1559-1564 2011年9月

Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C. 査読有り国際誌

Ishizu Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Goto H.

J Gastroenterol Hepatol 2011年

Association between HCV amino acid substitutions and outcome of peginterferon andribavirin combination therapy in HCV genotype 1b and high viral load. 査読有り国際誌

Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, Katano Y, Goto H.

JGastroenterol Hepatol. 25 巻 ( 6 ) 頁： 1072-1078 2010年7月

Impact of amino acid substitutions in the hepatitis Cvirus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. 査読有り国際誌

Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H.

Liver Int. 30 巻 ( 4 ) 頁： 554-559 2010年4月

Naofen, a novel WD40-repeatprotein, mediates spontaneous and tumor necrosis factor-induced apoptosis. 査読有り国際誌

Feng GG, Li C, Huang L, Tsunekawa K, Sato Y, Fujiwara Y, Komatsu T, Honda T,Fan JH, Goto H, Koide T, Hasegawa T, Ishikawa N.

Biochem Biophys Res Commun. 394 巻 ( 1 ) 頁： 153-157 2010年3月

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFNalpha-2b. 査読有り国際誌

Katano Y, Kumada T, Nakano I, Toyoda H, Ishigami M, Hayashi K, Honda T, Goto H.

Hepatogastroenterology. 56 巻 ( 90 ) 頁： 485-491 2009年3月

Mutations in the interferonsensitivity-determining region of hepatitis C virus genotype 2a correlate withresponse to pegylated-interferon-alpha 2a monotherapy. 査読有り国際誌

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Mutations in the interferonsensitivity-determining region of hepatitis C virus genotype 2a correlate withresponse to pegylated-interferon-alpha 2a monotherapy.

J Med Virol. 81 巻 ( 3 ) 頁： 459-466 2009年3月

Correlation of serum ribavirin concentration with pretreatment renal function estimates inpatients with chronic hepatitis C receiving combination antiviral therapy withpeginterferon and ribavirin. 査読有り国際誌

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A,Atsumi H, Nakano S, Arakawa T, Honda T, Hayashi K, Katano Y, Goto H.

J Viral Hepat. 15 巻 ( 9 ) 頁： 651-658 2008年9月

Regulation of branched-chain amino acid catabolism in rat models for spontaneous type 2 diabetes mellitus 査読有り国際誌

Kuzuya Teiji, Katano Yoshiaki, Nakano Isao, Hirooka Yoshiki, Itoh Akihiro, Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Goto Hidemi, Fujita Yuko, Shikano Rie, Muramatsu Yuji, Bajotto Gustavo, Tamura Tomohiro, Tamura Noriko, Shimomura Yoshiharu

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 373 巻 ( 1 ) 頁： 94 - 98 2008年8月

Use of the Model for End-Stage Liver Disease (MELD) score topredict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. 査読有り国際誌

Ishigami M, Honda T, Okumura A, Ishikawa T, Kobayashi M, Katano Y, FujimotoY, Kiuchi T, Goto H.

J Gastroenterol. 43 巻 ( 5 ) 頁： 363-368 2008年7月

Association of hepatitis B virussubgenotypes and basal core promoter/precore region variants with the clinicalfeatures of patients with acute hepatitis. 査読有り国際誌

Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, Hirooka Y, NakanoI, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Gastroenterol. 43 巻 ( 7 ) 頁： 558-564 2008年7月

*Effect of Ribavirin, Combination with Interferon in Patients with Hepatitis C, on the Bleeding Risk Associated With Selective Serotonin Reuptake Inhibitors 査読有り国際誌

Takashi Honda,Yoshiaki Katano,Hidenori Toyoda,Kazuhiko Hayashi,.Masatoshi Ishigami,Isao Nakano,Hidemi Goto,Koji Yamamoto,Junki Takamatsu

J Clin Psychatry 69 巻 ( 4 ) 頁： 679 - 680 2008年4月

Prevalence of Hepatitis E Virus IgG Antibody in Japanese Patients with Hemophilia 査読有り国際誌

Toyoda H, Honda T, Hayashi K, Katano Y, Goto H, Kumada T, Takahashi K, Abe N, Mishiro S, Takamatsu J

Intervirology 29 巻 ( 51 ) 頁： 21-25 2008年2月

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. 査読有り国際誌

Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H.

J Gastroenterol Hepatol. 22 巻 ( 11 ) 頁： 1929-1935 2007年11月

Changes in circulating cytokine levels and lymphocyte subsets in healthy liver donors after partial hepatectomy 査読有り国際誌

Nakashima S, Katano Y, Nakano I, Hirooka Y, Ito A, Ishigami M, Hayashi K, Honda T, Goto H

Hepatol Res. 37 巻 ( 10 ) 頁： 878-84 2007年6月

Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. 査読有り国際誌

Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Yano M, Goto H, Yoshioka K, Toyoda H, Kumada T.

J Med Virol. 79 巻 ( 4 ) 頁： 366-373 2007年4月

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B 査読有り国際誌

Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, Hirooka Y, Itoh A, Goto H

J Med Virol. 79 巻 ( 1 ) 頁： 35-40 2007年1月

Difference of HBV genotype distribution between acute hepatitis and chronic hepatitis in Japan 査読有り国際誌

Takeda Y, Katano Y, Hayashi K, Honda T, Yokozaki S, Nakano I, Yano M, Yoshioka K, Toyoda H, Kumada T, Goto H

Infection 34 巻 ( 4 ) 頁： 201-207 2006年8月

Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load 査読有り国際誌

Ukai K, Ishigami M, Yoshioka K, Kawabe N, Katano Y, Hayashi K, Honda T, Yano M, Goto H

World J Gastroenterol. 12 巻 ( 23 ) 頁： 3722-3728 2006年6月

Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver 査読有り国際誌

Ishiguro H, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, Goto H, Bajotto G, Maeda K, Shimomura Y

Life Sci. 79 巻 ( 8 ) 頁： 737 - 743 2006年4月

*Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin 査読有り国際誌

Yamamoto K, Honda T, Matsushita T, Kojima T, Takamatsu J

J Thromb Haemost. 4 巻 ( 2 ) 頁： 469-470 2006年2月

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan 査読有り国際誌

Kumada T, Toyoda H, Honda T, Kuzuya T, Katano Y, Nakano I, Goto H

Intervirology 49 巻 ( 1-2 ) 頁： 112-118 2006年1月

Branched-chain amino acid catabolism in exercise and liver disease 査読有り国際誌

Shimomura Y, Honda T, Shiraki M, Murakami T, Sato J, Kobayashi H, Mawatari K, Obayashi M, Harris RA

J Nutr. 136 巻 ( 1 ) 頁： 250S-253S 2006年1月

Recurrent hepatocellular carcinoma with rapid growth after cardiac surgery 査読有り国際誌

Shimizu H, Katano Y, Nagano K, Yokozaki S, Shimizu F, Naito T, Hayashi K, Shimizu Y, Honda T, Kaneko T, Akita S, Nakano I, Fukuda Y

Hepatogastroenterology 52 巻 ( 66 ) 頁： 1863-1866 2005年11月

Clearance of GB virus C during highly active antiretroviral therapy and course of HIV disease progression in HIV-infected patients with hemophilia. 査読有り国際誌

Toyoda H, Honda T, Katano Y, Goto H, Takamatsu J

Eur J Clin Microbiol Infect Dis. 24 巻 ( 9 ) 頁： 645-646 2005年9月

Impact of tumor factors on the prognosis of patients with advanced cirrhosis (Child-Pugh class C) and hepatocellular carcinoma 査読有り国際誌

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kuzuya T, Nonogaki K, Shimizu J

J Gastroenterol Hepatol. 20 巻 ( 6 ) 頁： 963-965 2005年5月

Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy 査読有り国際誌

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kuzuya T, Honda T, Hayashi K, Nakano I, Katano Y, Goto H

Clin Infect Dis. 40 巻 ( 6 ) 頁： e49-54 2005年3月

*Regulation of branched-chain amino acid metabolism and pharmacological effects of branched-chain amino acids 査読有り国際誌

Shimomura Y, Murakami T, Nagasaki M, Honda T, Goto H, Kotake K, Kurokawa T, Nonami T

Hepatol Res. 30S 巻頁： 3-8 2004年12月

Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan 査読有り国際誌

Toyoda H, Hayashi K, Murakami Y, Honda T, Katano Y, Nakano I, Goto H, Kumada T, Takamatsu J

J Med Virol. 73 巻 ( 2 ) 頁： 195-199 2004年6月

Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan 査読有り国際誌

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kitabatake S, Kuzuya T, Nonogaki K, Kasugai T, Shimizu J

Cancer 100 巻 ( 11 ) 頁： 2415 - 2421 2004年6月

Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C 査読有り国際誌

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kuzuya T

Dig Dis Sci. 49 巻 ( 2 ) 頁： 295-299 2004年2月

Effects of liver failure on the enzymes in the branched-chain amino acid catabolic pathway. Biochem Biophys Res Commun 査読有り国際誌

Shimomura Y, Honda T, Goto H, Nonami T, Kurokawa T, Nagasaki M, Murakami T

Biochem Biophys Res Commun. 313 巻 ( 2 ) 頁： 381-385 2004年1月

*Comparison of contrast-enhanced harmonic ultrasonography and power Doppler ultrasonography for depicting vascularity of hepatocellular carcinoma identified by angiography-assisted CT 査読有り国際誌

Honda T, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Toyoda H, Ishiguro H, Ogawa S, Takeshima K, Kawachi T, Hibi T, Hayashi K, Katano Y, Fukuda Y, Goto H.

Hepatol Res. 27 巻 ( 4 ) 頁： 314 - 321 2003年12月

Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. 査読有り国際誌

Toyoda H, Kumada T, Hayashi K, Honda T, Morita K, Nishimura D, Imada K, Imoto M, Horiguchi Y, Nakano H, Nakano I, Fukuda Y

Cancer Detection and Prevention 27 巻 ( 6 ) 頁： 498-502 2003年6月

ＨＩＶと肝障害（ＨＣＶ）査読有り国際誌

林和彦, 高松純樹, 本多隆, 横崎正一, 長野健一, 豊田秀徳, 片野義明, 中野功, 福田吉秀, 後藤秀実

日本エイズ学会誌 5 巻 ( 2 ) 頁： 101 - 106 2003年

Liver dysfunction among workers handling 5-nitro-o-toluidine 査読有り国際誌

Shimizu H, Kumada T, Nakano S, Kiriyama S, Sone Y, Honda T, Watanabe K, Nakano I, Fukuda Y, Hayakawa T

GUT 50 巻 ( 2 ) 頁： 266 - 270 2002年2月

Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy 査読有り国際誌

Hayashi K, Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Toyoda H, Shimizu H, Honda T

HEPATO-GASTROENTEROLOGY 49 巻 ( 44 ) 頁： 508 - 512 2002年

Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C 査読有り国際誌

Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, Hayakawa T, Fukuda Y

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 16 巻 ( 10 ) 頁： 1131 - 1137 2001年10月

Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C 査読有り国際誌

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T

ONCOLOGY 61 巻 ( 2 ) 頁： 134 - 142 2001年

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C 査読有り国際誌

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y

JOURNAL OF VIRAL HEPATITIS 7 巻 ( 6 ) 頁： 414 - 419 2000年11月

　前のページ - 次のページ　

<本多 隆>

論文 - 本多 隆

<本多　隆>

論文 - 本多　隆